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The biomedical data grows dramatically year-by-year. Especially with the completion of 
sequencing by the Human Genome Project, the biological research enters the postgenomic 
era. To well manage and use these fast-growing data, a large number of biological 
databases are created as well as various data analysis tools. In this work, studies have been 
focused on the development of biological databases and their applications in biomedical 
research and drug discovery.  
 
The development of database is a complex and time-consuming process. The entire 
process is carried out stage by stage, from data preparation, database construction, to 
database representation. Different technologies are used in different stages of database 
development, e.g. information retrieval (IR) and text mining (TM). Following the strategy 
of database development, two biological databases were developed in this work: the Drug 
Adverse Reaction Target database (DART) and the Kinetic Data of Biomolecular 
Interaction database (KDBI). DART collects the literature recorded protein targets that are 
able to induce, directly or indirectly, the adverse drug reactions (ADRs). Efforts have been 
made to gather the related information such as the physiological function of each target, 
binding drugs/agonists/antagonists/activators/inhibitors, corresponding adverse effects, 
and type of ADR induced by drug binding to a target. This work has been published in the 
international journal Drug Safety [Ji et al., July 2003].  KDBI was created which aims at 
providing experimentally determined kinetic data of bio-molecular interaction such as 
protein-protein and protein-nucleic acids described in the literature. Such information is 
important for mechanistic investigation, quantitative study and simulation of cellular 
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processes and events. This work has been published in the international journal of Nucleic 
Acids Research in 2003 [Ji et al., January 2003]. 
 
In addition to simply providing the information, further analysis on these two databases 
was made. Two knowledge discovery applications of the DART database were 
investigated. One of them intended to identify the ADR targets based on protein primary 
sequences using the learning algorithm of Support Vector Machines (SVMs). A model 
was constructed, trained and optimized using known ADR targets of DART database as 
positive data. The optimized model was later able to classify the potential ADR targets 
and non-ADR targets. Similar work of protein family classification using SVM was 
published in Nucleic Acids Research [Cai et al., 2003]. The knowledge discovery of 
DART database was also made to facilitate drug discovery. In this work, the potential 
ADR targets of 11 marketed AIDS drugs were predicted by searching the DART database. 
The prediction involved a docking software INVODOCK, which is able to optimize the 
drugs docking into the proteins by searching the protein cavity database. For each studied 
drugs, the docked proteins were listed. They are the possible targets while the drug is 
admitted to the body. These proteins include the potential therapeutic targets, ADME 
(Absorption, Distribution, Metabolism, Excretion)-associated proteins, and ADR targets. 
A good way to identify these targets is searching the respective target databases. For 
example, by searching the drug adverse reaction targets database DART, one can easily 
figure out whether the studying drug is safe enough and what kinds of adverse effects it 
may induce. Respective target databases for therapeutic targets [Chen et al., 2002] and 
ADME-association proteins [Sun et al., 2002] were constructed previously with the effort 
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of our group members. Finally, a databases-supported Computer-Aided Drug Discovery 
system (CADD) was established and studied.  
 
The knowledge discovery of kinetic database KDBI was also studied by the construction 
of protein-protein interaction network. Comparing to other similar networks available on-
line, all of the protein-protein interactions in the KDBI are confirmed by the literature with 
kinetic value. Such protein-protein interaction network facilitates biological pathways 
study both in quantity and quality. It is also helpful for the identification of new 
therapeutic targets, even drug discovery. The network is still preliminary and will be 
extended and consolidated with more new data added in. 
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CHAPTER 1 INTRODUCTION 
 
1.1 History of Database Technology 
 
Database and Database Management System (DBMS) is one of the most important classes 
of modern information technology. The term “data base” is thought to be adopted first by 
the SDC, the Rand Corporation group around 1960, which described the shared collection 
of information on which all these views were based [Haigh et al., 2003]. The development 
of the first database was involved as part of the famous SAGE anti-aircraft command and 
control project, which was the first major system able to respond immediately and directly 
to representations of various information to all users. This requires the management of 
central, electronic and instantly accessible file of enormous size. As a result, such system 
was invariably written in low-level assembly language in mid-1960s, when few practical 
tools were available for use in the construction of a database. However, by that time, the 
concept of management system of database was not formed yet. Until 1968, the term “data 
base management system” was standardized by the Data Base Task Group (DBTG), by 
combining two previously separated concepts: the formerly vague “data base” itself and 
the well defined “file management” or “information storage” software. The acceptance of 
the DBMS concept implicitly redefined the “data base”, which became a new, narrower 
and much clearer idea. At present, data base is an integrated collection of data, usually 
stored on the secondary storage devices such as disks or tapes, and maintained by DBMS. 
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The application of databases is broad, both in the academia and industries. This thesis 
reports our research on the development of biological databases and their applications in 
drug discovery and knowledge discovery in specific areas of biomedical science. The 
relevant technologies of database development and knowledge discovery are discussed as 
well. 
 
1.2 Development and Categories of Biological Databases 
1.2.1 History of biological databases development 
 
In the early days, when a database containing 200 entries of nucleic acids sequence was 
opened for public access [Dayhoff et al., 1980], the general opinion was doubtful 
regarding the ability of biological databases to aid in biomedical research. Now, it 
becomes a routine procedure for the researchers to search specific biological databases to 
address some questions before expensive experiments are carried out. The latest database 
issue of Nucleic Acids Research lists about 400 different databases covering diverse areas 
of biological research [Baxevanis et al., 2003] including primary sequence, genetics, 
intermolecular interactions, pathways, pathology, proteomics, structure and medical 
information.  
 
The increase is not only in the number of the databases, but also in their size and 
complexity. Today, biological databases can be huge in size as the large-scale primary 
archiving projects, such as GenBank and SWISS_PROT. For example, the major protein 
database SWISS_PROT contains 12,7863 entries as of June of 2003. In each entry, a 
variety of information is included, for example, protein name, synonym, gene name, 
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organism species, primary sequence, taxonomy cross-reference, physiological function, 
domain. and many cross-links to other databases. Furthermore, to easily access a database, 
a powerful searching engine is provided for keyword or ID search, as well as some useful 
Bioinformatics tools such as sequence alignment. Facing the ever-increasing data, flat files 
database management systems, which were used for storage and representation of data by 
databases of early ages, are no longer sufficient for the present day biological databases. 
The more powerful and functional database management systems such as the Relational 
Database Management Systems (RDBMS) are in demand to efficiently maintain the 
comprehensive and cross-related information stored in databases. At the same time, 
internet technologies such as World Wide Web (WWW) and visualization technologies 
are acquired to make the representation of databases more user-friendly. Recently, there 
appears to be a trend for the traditional databases to evolve into knowledge bases. 
Therefore, various knowledge discovery technologies have been developed and employed, 
that will be discussed in a later section.  
 
1.2.2 Categories of biological databases 
 
Today there are a large number of databases available on-line ranging from the large–scale 
project archives such as SWISS-PROT to individual, specialized collection such as 
Receptor Database [Nakata et al., 1999]. According to the scope of databases, a biological 
database can be grouped into three categories [Frishman et al., 1998]: 
 
General biological databases, which store the raw data of DNA/protein sequence, 
structure, and biological and medical literature. Examples include: the nucleic acid and 
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protein primary sequence databases such as GenBank [Benson et al., 1999] by National 
Center of Biotechnology Institute (NCBI), Nucleotide database of European Molecular 
Biology Laboratory (EMBL) [Stoesser et al., 1998], and DNA Data Bank of Japan (DDBJ) 
by the National Institute of Genetics (NIG), Japan [Tateno et al., 2002]; the protein 
databases such as Protein Knowledgebase SWISS-PROT/TrEMBL [Bairoch et al., 2000] 
by Swiss Institute of Bioinformatics (SIB) and European Bioinformatics Institute (EBI), 
Protein Information Resource (PIR) by Georgetown University Medical Center (GUMC), 
USA [Wu et al., 2002]; the original structure databases such as Protein Data Bank (PDB) 
by Rutgers, The State University of New Jersey, USA [Sussman et al., 1998], the 
Structural Classification of Proteins database (SCOP) by Medical Research Council 
(MRC), Cambridge, UK [Murzin et al., 1995]; the biological and medical literature 
databases like MEDLINE by NCBI [Wheeler et al., 2003]. Databases of this category are 
repositories of original experimental results. They are normally huge in size and operated 
by some well-known large research institutes, however, there are also some comparatively 
small databases in this category such as the searchable database of multidimensional 
biological images, BioImage by EBI [Carazo et al., 1999]. Sometimes international 
collaborations of research institutes help to standardize and enrich the databases. The 
typical such cooperation is the International Nucleotide Sequence Database Collaboration 
among GenBank, EMBL and DDBJ (Figure 1.1). Generally, databases of this category are 
a basis for other databases, bioinformatics tools and commercial software. 
 
Derived databases, whose data are derived from the general biological databases, but 
that, contain novel information. For example, the database of protein families and domains 
(PROSITE) consists of biologically significant sites, patterns and profiles that help to 
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reliably identify to which known protein family (if any) a new sequence belongs [Bairoch 
et al., 1994]; the protein families database (Pfam) is a large collection of protein multiple 
sequence alignments and profile hidden Markov models based on protein primary 
sequence databases [Bateman et al., 2002]. Databases of this category generate their novel 
information by analyzing or mining the primary sequence, structure of nucleotides or 
proteins. The generation process is normally through certain Bioinformatics software or 
algorithms such as multiple sequence alignments automatically working on the large 
volume of raw data.  Databases of this category regenerate novel information regularly 
when the respective raw data source is updated. 
 
Subject-specialized databases, which collect individual, specialized information for 
communities with particular interests. Databases of this category can include databases 
with original experimental data or derived databases that are based on the general 
databases. The characteristics of these databases are: subject-specialized, compact in size, 
and comprehensive in converting their respective subject. The examples include the 
protein specialized databases: the Comprehensive Enzyme Information System 
(BRENDA), developed at the Institute of Biochemistry at the University of Cologne that 
mainly collects enzyme functional data [Schomburg et al., 2002]; Another enzyme 
nomenclature database (ENZYME) also provides similar information, which is maintained 
by SIB [Bairoch et al., 2000]; the G-protein coupled receptor database (GCPRD) collects, 
combines, validates and disseminates heterogeneous data on G protein-coupled receptors 
(GPCRs) [Horn et al., 1998]; the pathways databases: Kyoto Encyclopedia of Genes and 
Genomes PATHWAY (KEGG PATHWAY) is the primary database resource for the 
computerized knowledge on molecular interaction networks such as pathways and 
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complexes [Kanehisa et al., 2002]; the PathDB developed by National Center for Genome 
Resources (NCGR), USA, is both a data repository and a system for building, visualizing, 
and comparing cellular networks (http://www.ncgr.org/pathdb/); the gene databases: 
Transcription Regulatory Regions Database (TRRD) is an informational resource 
containing an integrated description of the gene transcription regulation [Kolchanov et al., 
2002]; BodyMap focuses on human and mouse gene expression that is based on site-
directed 3'-expressed sequence tags generated at Osaka University [Sese et al., 2001]; the 
intermolecular interaction databases: the Biomolecular Interaction Network Database 
(BIND) archives biomolecular interaction, complex and pathway information [Bader et al., 
2003]; the Database of Interacting Proteins (DIP) documents experimentally determined 
protein-protein interactions [Xenarios et al., 2000]. There are many other subject-
specialized databases available for the interests of different communities; for example, our 
therapeutic target database (TTD) is especially designed for the identification of the 
therapeutic target proteins documented in the literature [Chen et al., 2002]. Subject-
specialized databases make up the major portion of the biological databases, especially, 
the small and medium size databases. These are functional databases and often able to aid 
in biological/medical research, drug discovery, and human healthcare. 
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1.3 Role of Database in Analyzing Biomedical Data 
1.3.1 Analysis of biomedical data with databases 
 
At the end of 20th century, with the efforts of some individual genomics companies and 
the international Human Genome Project groups, the entire human genome has been 
sequenced. When the applause for this grand achievement is fading, more challenging 
tasks emerge. The challenges are how to identify the genes and other functional fragment 
from the vast raw genetic sequence? How to figure out the physiological functions of the 
proteins or peptides coded by those genes? In the long-term, how to elucidate the 
“underlying molecular mechanisms of disease and thereby facilitating the design in many 
cases of rational diagnostics and therapeutics targeted at those mechanisms” [Waterston 
et al., 2002]. To answer these questions experiments alone are not enough, and sometimes 
beyond reach in the near future. A better solution is to combine experimental data and 
technologies of informatics to seek the clues, which has introduced a new discipline: 
Bioinformatics. Biological database technology is one of important area of Bioinformatics. 
Database organizes biological data in a rational way, which offers a platform for further 
analysis and knowledge discovery from these data. Development and application of 
biological databases have pushed and accelerated the development of Bioinformatics as a 
discipline.  
 
Bioinformatics is the computer-assisted data management discipline that helps us gather, 
analyze, and represent biological information in order to understand life's processes 
[Persidis et al., 1999]. As described in the Oxford English Dictionary, the definition of 
Bioinformatics is “conceptualizing biology in terms of molecules and applying 
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‘informatics techniques’ to understand and organize the information associated with these 
molecules, on a large scale. In short, bioinformatics is a management information system 
for molecular biology and has many practical applications”. 
 
The start of Bioinformatics can be traced back to mid 1970s, when automated protein and 
DNA sequencing became available. The early application of bioinformatics was typically 
associated with database of gene/protein sequences, when the databases were accessed 
locally and with limited analysis tools. With the development of internet technology, in 
the late 1980s, those databases were also accessible remotely, and more analysis tools 
became available. From the 1990s on, the popular use of internet and the explosion of 
biological data, in some sense, has made Bioinformatics equally attractive to academic 
and company scientists. And because of the efforts of these scientists and funding 
agencies such as NIH in USA and EMBL in Europe, Bioinformatics became more and 
more prominent and diverse. 
 
Biomedical data analysis of different levels 
 
In definition, the ability of Bioinformatics is to gather, store, classify, analyze, distribute, 
simulate, and predict biological information derived from sequencing, functional analysis 
projects such as protein 3D structure analysis, metabolic pathways simulation, human 
genes extraction and literature of biological and medical research. The technologies used 
in Bioinformatics which include databases, different kinds of analysis tools based on 
sequence, structure and function, drug design assistant system, or data mining (knowledge 
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discovery) based on databases. According to the aims of these technologies, biomedical 
data analysis can be roughly categorized into three levels. 
 
At the first level, the biological data is collected and well organized so that users are 
allowed to access and retrieve the information for further analysis. The most important 
and typical technology at this level is a database. Data from different source is collected 
and deposited in respective databases. To well organize the vast, high-dimensional, cross-
related data, a good data structure and database management system (DBMS) are desired. 
The data warehouse technology, and some commercial Relational Database Management 
System (RMDBS) such as ORACLE and SYBASE are thus adopted. For most of public and 
commercial biological databases, a user-friendly interface to the databases and internet 
remote access is also provided, through which the data is distributed worldwide for further 
data analysis.  
 
Databases are widely used in academic research, therapy support, and therapeutic industry. 
A good database can reduce aid in research, clinical diagnosis, and new drug discovery. A 
good example is therapeutic decision-making in stages III and IV head and neck cancer 
treatment [Gleich et al., 2003]. The cases of head and neck cancer in the patient databases 
were reviewed and analyzed using the Kaplan-Meier method. It was found that the age, 
co-morbidity, and advanced stage on survival of patients were closely linked. Thus, the 
site and stage-specific treatment based on the data in the databases would be useful in 
counseling patients with advanced head and neck cancer. Searching databases for 
answering specific questions has become a routine practice for most researchers. This 
trend has brought up the tide of development of databases and the analysis software based 
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on the databases in recent years. Other than the well constructed databases, much 
information on-line is simply listed in flat files or tables. These web pages or tables are 
commonly specialized on certain topics. They are more focused though they may be small 
in size and limited in the completeness of information. One example is the page of 
PROLYSIS on the protease and protease inhibitors at (http://delphi.phys.univ-
tours.fr/Prolysis/index.html). Another typical example is the page of Tools for Glutamate 
Receptor Research by University of Bristol at 
(http://www.bris.ac.uk/synaptic/info/tools.html), which details agonists and antagonists for 
NMDA, AMPA/Kainate and mGlu receptors. 
 
Once the data is made available, an analysis of these data becomes possible. At the second 
level of Bioinformatics, a number of data analysis tools are developed. These tools use the 
raw data or derived data of DNA/protein sequence, structure, and literature information to 
generate new information. For example, sequence alignment tools FASTA [Pearson et al., 
1988] is able to search DNA/Protein sequence databases, evaluate similarity scores, and 
identify periodic structures based on local sequence similarity. Similar tasks can also be 
done by BLAST [Altschul et al., 1997]. Other tools include translating nucleic acid 
sequence to peptide; protein identification and characterization; pattern and profile 
searches; primary structure analysis. A list of such tools can be found in ExPASy 
Proteomics tools page (http://tw.expasy.org/tools/), which are free for researchers. EMBL-
EBI Toolbox also collects different categories of tools for the fields of Bioinformatics 
(http://www.embl-ebi.ac.uk/Tools/index.html). Comparing to the free tools on-line, some 
Bioinformatics companies develop commercial Bioinformatics software of more functions 
and abilities. For example, the molecular modeling software SYBYL developed by 
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TRIPOS is a program able to build, study and manipulate molecules including 
macromolecules like nucleic acids and proteins. It also provides some powerful tools for 
molecular dynamics, energy minimization, homologous modeling. Special hardware, e.g. 
SGI graphic workstation, is required to ensure the program work properly. Similar 
commercial software of Bioinformatics is INSIGHT II developed by ACCELRYS.  
 
Bioinformatics tools such as sequence alignments, pattern searches are able to analyze the 
raw data, thus to summarize the useful rules or information, even to simulate protein 
structure or the biological systems such as metabolic pathway. However, some tools for 
the analysis, calculation, and simulation may be inadequate for the practical application 
such as the pharmaceutical industry. Extracting the hidden meaningful information from 
the data pools and further predicting the new events in advance is expected. For example, 
how to identify the individual genes from the DNA sequence? How to predict the protein 
structure based on the sequence? How to predict protein/protein or protein/ligand 
interactions? Fortunately, the introduction of new knowledge discovery technologies and 
algorithms make these attempts possible. A good example is the application of data 
mining technologies such as SVM, decision trees in gene identification [Rosenquist et al., 
2001], protein/protein interaction prediction [Bock et al., 2001] and therapy support 
[Dusseldorp et al., 2001]. These approaches are not yet mature, and more new 
technologies and algorithms are being introduced to further improve them. More about 
data mining will be discussed later.  
 
In conclusion, the flood of biological data has catalyzed the construction of databases for 
the data storage and distribution. It has also stimulated the development of respective data 
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analysis tools and software. The Bioinformatics tools/software are applied in life science 
research [Boguski et al., 2003], medical research [Lynn et al., 2003], therapy decision-
making [Sarachan et al., 2003], pharmaceutical industry [Liebman et al., 2002] and many 
other biological relevant fields. For example, support vector machines (SVMs) software 
was used to analyze the microarray expression data thus classify and validate the cancer 
tissue samples from normal tissue samples [Furey et al., 2000]. Many new molecular-
based technologies such as Genomics, Proteomics, transcriptional profiling, gene 
expression patterns and respective software have been applied in new drug discovery. The 
complete genome sequence information of human, bacteria, and virus, with subsequent 
bioinformatics analytic tools may support computer-aid drug design [Haney et al., 2002]. 
The databases and Bioinformatics software is developed for different purposes; however, 
it is widely acknowledged that the long-term value or final object of Bioinformatics is not 
the development or use of tools, but knowledge discovery so as to improve the human 
health.  
 
1.3.2 An example: database for kinetic study of biomolecular 
interactions 
 
Proteins and nucleic acids can be regarded as one of the basis of the modern molecular 
biology. Almost all the biological events involve proteins or nucleic acids. The study of 
biological events is the way for us to understand human body behavior, possible etiology 
and therapy. Such study can be carried out in three progressive stages: first is the 
physiological function of individual molecule itself, second the interaction between the 
bio-molecules, and finally the cellular process composed of different bio-molecular 
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interaction. The discovery of physiological functions of biomolecules is normally by 
repeating experiments such as catalyzing analysis and binding analysis on the respective 
molecules. Unfortunately, it is costly to try all the analysis to determine the molecular 
function. An alternative way is through the use of Bioinformatics analysis tools for 
facilitating function discovery.  One can compare the respective protein primary sequence 
with the sequences deposited in databases such as SWISS_PROT or GenBank by using 
sequence alignment tools such as BLAST and FASTA. It is believed that homology in 
protein primary sequence always indicates similarity in physiological function. The 
prediction of protein function can be further verified by rationalized and focused 
experiments. The interaction between molecules, including protein-protein, protein-
nucleic acids and protein-ligand, is normally identified by binding experiments and kinetic 
analysis. The binding analysis confirms the interaction between the molecules, while the 
kinetic analysis reveals the time course of the interaction. Cellular processes and 
underlying molecular events involve complex interactions and cross talks between 
individual molecules, pathways and networks of pathways [Downward et al., 2001; 
Lengeler et al., 2000]. Simply, the cellular processes or biological pathways are the 
networks of molecular interactions, which are often used as the clues of etiology and 
therapy. The distinctive interactions are connected to each other and may affect others. 
The effects of upstream molecules on the downstream molecules are unequally, however, 
quite different due to different possibilities of reaction happening. Therefore, quantitative 
as well as mechanistic understanding of these interactions is important for exploration and 
engineering of cell behavior and for the development of novel therapeutics to combat 
diseases.  A number of databases of molecular interactions [Bader, 2001; Xenarios, 2002], 
pathways [Goto et al., 1997; Igarashi et al., 1997; van Helden et al., 2000] and enzyme 
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reactions [Goto et al., 1998] have been developed. These databases provide 
comprehensive information about interacting molecules, molecular complexes, pathways, 
chemical reactions, and conformation changes. The kinetic data for these interactions, 
important for mechanistic investigation, quantitative study and simulation of cellular 
processes and events [Sahm et al., 2000; Fussenegger et al., 2000; Haugh et al., 2000], is 
not provided in the existing databases. Therefore, in this work, a Kinetic Data of 
Biomolecular Interaction database (KDBI) is developed to provide kinetic information for 
protein-protein, protein-ligand, and protein-nucleic acids interactions.  Furthermore, 
knowledge discovery from the KDBI database is tried to construct the protein-protein 
interaction network, which could be part of biological pathways. It is expected that both 
the kinetic database KDBI and its derived protein-protein interaction network will help to 
better understand of disease etiology and better therapy.   
 
1.4 Role of Databases in Facilitating Drug Discovery 
1.4.1 Overview of emerging technologies of drug discovery 
 
Drug discovery is complex and costly process. It is an innovative, creative, and iteratively 
experimental science, which is more than the application of basic research knowledge and 
technologies [Black et al., 1986]. It involves many facets of project management and 
research [Jacques et al., 1992].   
 
Generally, before a drug reaches the market, it needs to go through three main stages: drug 
discovery and testing in the lab, clinical evaluation, and market feedback (Figure 1.2). 
Each stage of new drug development is time-consuming and costly, especially the initial 
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stage of drug discovery, which can last up to 20 years. Thousands of candidate compounds 
are screened, and only a limited number and success of compounds reach pre-clinical 
development for their activity, efficacy, selectivity, bioactivity, and pharmacokinetics 
studies. The pre-clinical development process may take up several years depending on the 
number of the compounds. Those compounds that fulfill the clinical requirements, 
normally only few, will be evaluated in further clinical trials. The clinical trials are 
composed of four phases: Phase I studies determine safety of compound in normal human 
volunteers using dose-ranging studies. Side effects as well as human pharmacokinetics are 
established at this stage. Phase II studies involve open-label, single- and multiple-dose 
studies in the patient population. Efficacy and bioactivity is determined at this stage. Phase 
III focuses on larger clinical trials proof of efficacy and the establishment of uncommon 
side effects and drug interactions.  Passing these three clinical trials, the drug candidates 
are eligible to submit to new drug controlling organisms such as FDA for approval of 
marketing.  In the first few years of marketing, the new drugs will still under supervision. 
The feedback of patients and doctors will be helpful for the dosage optimization, drug 
interaction and additional indications studies. The normal new drug discovery process is 
illustrated in Figure 1.2 using new drugs developed for African trypanosomiasis as 
example [Keiser et al., 2001]. The extremely high cost and the long research period makes 
the development of new drug more and more difficult. Therefore, reducing the costs and 
shortening the new drug development time would be a stimulator for the pharmaceutical 
industry. 
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Figure 1.2. The process of new drug development for African trypanosomiasis.  
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The history of drug development can be traced back to hundreds of years. However, 
modern drug discovery beginning from early 1940’s is mostly based on the synthetic 
chemistry, biology, biochemistry and pharmacology. The process of drug discovery was 
often dependent on natural sources and serendipity [Sneader et al., 1990]. A second phase 
of drug discovery began with the advances in enzymology and biochemistry. At this phase, 
designing drugs directly interacting with the distinct molecular target became possible. 
With the increase in computational power, drug discovery has entered a new phase of 
computer-driven drug discovery, Computer-Aided Drug Design (CADD), or Computer-
Assisted Molecular Design (CAMD). At this stage, further acceleration of drug discovery 
really becomes possible. 
 
Computer-Aided Drug Design (CADD) is a relatively new technology developed in the 
last decades. The development of CADD went in parallel with increase in computational 
power of computers. The demand of high computational power is because of the large 
calculation of the electronic properties of molecules, which is the foundation of the CADD. 
According to the focus of studying target/ligand interactions, the CADD approaches can 
be summarized into the following three groups: 
 
(1) Approaching the problems from the drug perspective with knowledge of the 
compound structure activity relationship (SAR) within series of pharmacophores. 
This approach is based on an assumption that the protein and ligand have limited 
degrees of flexibility [Saunders et al., 1989; Sim et al., 2002].  
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(2) Approaching the problems from the receptor or enzyme perspective with 
knowledge of the structure of the receptor or enzyme. The knowledge of the 
structure and 3D confirmation of the protein target provides an opportunity to 
identify the amino acid sequences and conformations that are responsible for 
ligand recognition and efficacy [Fritz et al., 2001; Wheatley et al., 1998].  
  
(3) Approaching the problems with information regarding the receptor/ligand, 
enzyme/substrate interaction derived by 2- or 3-D structural protein analysis 
methods. Compared to methods of previous categories, methods of this category 
pay more attention on the interaction between two molecules. The structural 
analysis methods include the nuclear magnetic resonance (NMR), X-ray 
crystallographic, and other methods. The impact of nuclear magnetic resonance 
(NMR) spectroscopy on rational drug design has recently increased through the 
description of the so-called structure-activity relationships (SAR) by NMR 
technique. The analysis of protein structures determined with minimal structural 
information by NMR can be extended with a particular interest in the utility of 
these structures for a structure-based drug design program [Huang et al., 2000; 
Wender et al., 1999].  
 
Looking at the detailed approaches and technologies, the most popular CADD 
technologies include structure-based approaches and quantitative structure-activity 
relationship (QSAR) approaches. The structure-based approaches attempt to design drugs 
in respective of based on the known protein structures, for example, the design of the HIV 
RT inhibitors based on the known HIV reverse transcriptase structure [Tantillo et al., 
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1994]. Structural methods such as X-ray crystallography or NMR technology have also 
been used to study inhibitor-target interactions for antitumor drugs design [Denny et al., 
1994]. When no experimental structure is available for the protein target, structures 
modeled by homology model are used to facilitate drug design [Teeter et al., 1994].  The 
docking approaches are a series of special structure-based approaches, which use 
computers to simulate the docking process of ligands to their protein receptor. Various 
docking approaches have been developed in recent years along with the increase of 
computational power. Different algorithms have been applied to more properly model the 
docking process and facilitate drug design [Krumrine et al., 2003]. In cases where the 
structure of the target protein is unknown and a modeled structure is difficult to derive, it 
is impossible to use the structure-based drug design. Rather, statistical learning based 
methods such as the QSAR approaches are applied. QSAR methods attempt to correlate 
biological activity with physical-chemical properties and structures of molecules. An 
example of its application is the successful design of the inhibitors for the HIV-1 protease 
by QSAR [Oprea et al., 1994]. In recent years, applications of QSAR in drug discovery 
have become supported by QSAR databases [Hansch, 1995; 
http://mmlin1.pha.unc.edu/~jin/QSAR/].  
 
1.4.2 The need of drug target databases for drug discovery 
 
Drug discovery and development is a complicated and long-term process. It is noticed that 
knowledge of protein targets of drugs (those proteins to which drugs bind and produce 
specific effects) play a crucial role in the disease etiology studies, pharmacokinetics 
studies, toxicity studies. Identification of these target proteins facilitates the design of 
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drugs with enhanced efficacy and reduced side effects that offer better treatment options 
for patients. In this work, the adverse drug reaction target database (DART) is created to 
facilitate the identification of potential toxicity targets to filter out the serious toxicity 
inducing drug candidates. It is expected that a series of target databases like DART are 
useful in facilitating rational drug discovery. Three kinds of target proteins are important 
for drug discovery: therapeutic targets, ADME (absorption, distribution, metabolism, and 
excretion) associated proteins, and adverse drug reaction (ADR)/toxicity targets.  
 
The proteins to which drugs specifically bind and elicit therapeutic effects are called 
“therapeutic targets”. Diseases are often caused by irregular inhibition or activation of 
certain proteins in biological pathways. The function of the drugs is to bind to specific 
proteins in the pathways to re-balance these pathways. Theoretically, all proteins in the 
pathways could be the potential targets of drugs. However, practically, only those that 
play essential roles in the pathological pathway regulation will be considered. Even under 
these circumstances, the selection of targets still needs to be prudent. For example, drugs 
should only act on pathological pathways but not on pathways controlling normal 
physiological functions; the selected target proteins should be sufficiently sensitive so that 
only small amount of drugs are needed to cause curative effects, which thus avoids the 
possible side effects due to the high dosage of drugs. A practical solution is to collect and 
study all the existing clinical and experimental therapeutic targets for different diseases.  It 
is estimated that there are approximately 500 therapeutic targets [Drews et al., 2000], the 
majority of which have been collected by our Therapeutic Target Database (TTD) [Chen 
et al., 2003].  
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The metabolite process of the drug candidates, from their intake until their excretion from 
the body, is important for the efficacy and bioactivity study. This process includes the 
absorption, distribution, metabolism, and excretion (ADME) of the drugs. Absorption is 
the process of the intake of drugs into the vascular system. Some drugs are small enough 
to directly absorb from the gastrointestinal system or other tissues into the blood stream; 
however, some need the assistance of the transporting proteins. The drugs in the blood 
stream will be delivered to the pathological tissue with the help of transporters/carriers. 
Some special transporters/carriers will even bring the drugs to the target proteins so that 
the drugs can then bind to the therapeutic target and cure the diseases. However, some 
drugs do not directly interact with their targets. These drugs will be metabolized and their 
products are the real agents to take effect. The metabolism process involves some 
particular protein families such as cytochrome P450s. The metabolites of drugs and the 
remaining drugs will be excreted out of the body with the help of some proteins. The 
deposit of drugs or their metabolites is one of the causes of the cytotoxicity. Therefore, a 
successful drug candidate should be absorbed and delivered to their target proteins, to be 
efficacious, whereas excess compounds should be easily removed from body so as to 
reduce the side effects. ADME-Associated Proteins database (MADE-AP) gathering such 
ADME associated proteins surely will be very helpful to identify those drug candidate 
with practical high efficacy and low toxicity [Sun et al., 2001].  
 
A successful drug should possess both high drug efficacy and low toxicity. The toxicity of 
the drug, or so-called drug adverse effect, is a major cause for the failure of drugs. The 
mechanisms leading to the induction of adverse drug reaction (ADR) are diverse. The 
drugs bind not only the therapeutic targets but also other proteins in the non-pathological 
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biological pathways; the drugs may irreversibly bind to the therapeutic targets due to the 
high dosage or their binding ability; the drugs or their metabolites may be deposited in the 
tissues, and the deposition disturbs the environment of cell such as pH environment and 
ion gradients and thus lead to the toxicity. Many factors are involved in the ADRs and 
often related to certain proteins. To systematically study the mechanisms of the ADRs and 
reduce the possible ADRs during drugs discovery, it is necessary and meaningful to 
collect all the proteins inducing, directly or indirectly, the ADRs. Therefore, in this work, 
a drug adverse reaction targets database (DART) is created to collect such ADR target 
proteins.  
 
1.4.3 Adverse drug reaction target database for drug safety evaluation 
 
All drugs can produce harmful as well as therapeutic effects. As the definition of the 
World Health Organization (WHO), adverse drug reaction (ADR) is “any noxious, 
unintended, and undesired effect of a drug, which occurs at doses used in humans for 
prophylaxis, diagnosis, or therapy.” This excludes therapeutic failures, intentional or 
accidental poisoning or drug abuse, and adverse effects due to errors in administration or 
compliance.  The forms of ADRs vary from a single physiological/biochemical parameter 
to multiple organ failure. According to the clinical perspective, the ADRs can be classified 
as following [Park et al., 1994]: 
 
Type A: These reactions are predictable in terms of the known pharmacology of 
the drug and are usually dose dependent. 
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Type B: These reactions are unpredictable from knowledge of the basic 
pharmacology of the drug and do not show any simple dose-response relationship. 
Type C: These reactions are associated with long-term drug therapy. 
Type D: These reactions are due to the delayed effects. 
 
The majority of the ADRs in human are of pharmacological nature. It is estimated that 
about 75% of the ADRs are type A adverse reactions, which are dose-dependent and 
normally reversible. It is believed that all the drugs may cause dose-dependent adverse 
effects. This type of ADRs is predictable, and can sometimes be reduced or even removed 
when the drugs dosage is reduced or drug treatment discontinused. In contrast to type A 
adverse reactions, type B ADRs lack correlation between the dose and the toxicity. They 
are often serious and sometimes even lead to death. Fortunately, this type of ADRs is rare.  
 
The adverse effects induced by drugs are dangerous. They hinder the cure of patient, and 
they are also the causes of many instances of morbidity. Therefore, the understanding of 
the possible mechanisms of ADRs would be helpful for the successful treatment of 
patients. The cause of adverse drug reactions often result from interaction of a drug or its 
metabolite with either its main therapeutic target or other protein and nucleic acid targets 
important in the normal cellular functions [Pumfor et al., 1997; Wallace et al., 2000; Park 
et al., 2000; Rang et al., 1999; Klaassen et al., 2001; Baynes et al., 1999]. Identification 
and characterization of these adverse effect related protein or other molecular targets 
constitutes a major focus of pharmacology and toxicology research [Klaassen et al., 2001; 
Kong et al., 1999; Monks et al., 1998]. Knowledge about these targets not only facilitates 
the study of the mechanism of ADR, it has also been widely used in the development of 
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experimental techniques and computer tools for molecular analysis and high-throughput 
screening of ADRs as an early risk assessment tool [Gerhold et al., 1999; Nuwaysir et al., 
1999; Barratt et al., 1998; Chen et al., 2001]. Rapid advance in genetic [Peltonen et al., 
2001], structural [Sali et al., 1998] and functional [Koonin et al., 1998] genomics is 
providing increasingly more comprehensive information about adverse effect related 
genes, proteins and pathways. This helps to broaden the scope of drug safety evaluation 
R&D to include such tasks as analysis of pharmacogenetic implication of sequence 
variation or expression pattern alterations of adverse effect targets [Smith et al., 2001; 
Pirmohamed et al., 2001; Vesell et al., 2000].  
 
Traditionally, knowledge about known ADR targets is extracted from literature search, 
which can be time consuming and difficult particularly for non-expert. Therefore, a 
publicly accessible database with comprehensive information about these targets provides 
a convenient and useful platform for obtaining relevant information. The information of 
particular interest includes the functional aspects of ADR targets, mode of interaction of a 
target with binding drugs and ligands, as well as the adverse effect due to the binding of a 
drug or a chemical to each target. To the best of our knowledge, such a publicly accessible 
database is not yet available. Thus, we construct a Drug Adverse Reaction Target (DART) 
database, which contains information about the literature-described known targets related 
to adverse effects of drugs [Ji et al., 2003].  
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1.5 Databases Knowledge Discovery 
1.5.1 Key role of data mining in evolution of data bases into 
knowledge bases 
 
Today, databases along with their supporting DBMSs are widely used in academic 
research, business, and industries. Database use grows quickly with the expansion of the 
internet. It is noticed that the development of the database is not limited to its application 
in various domains, but also the database itself. Good integration of data, efficient 
searching and retrieval engine, and convenient but powerful management has become a 
characteristic of well-constructed databases. However, that is not enough. The final 
objective of databases is offering useful information, the knowledge, rather than some 
unrelated plain data. Therefore, databases should present more than data that are to 
difficult to understand, but the information they contain; in other words,  “data base” 
should evolved into “knowledge base”. The evolution of knowledge bases is a variable 
process. However, it contains one critical step, which is the knowledge discovery from the 
databases. In Figure 1.3, the process of database evolution is illustrated. The data 
deposited in the databases is transformed and mined for patterns using different 
knowledge discovery technologies. The patterns are further interpreted as knowledge. 
Thus, the “data base” successfully evolved to “knowledge base”. During this evolution 
process, data mining plays an important role.  
 
Data mining, sometimes also called Knowledge Discovery in Database (KDD), has been 
defined as “the nontrivial extraction of implicit, previously unknown, and potentially 
useful information from data” [Frawley et al., 1992]. It is a powerful new technology with 
great potential to extract the most important information from data warehouses. Data 
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mining tools predict future trends and behaviors, allowing businesses to make proactive, 
knowledge-driven decisions. The automated, prospective analyses offered by data mining 
move beyond the analyses of past events provided by retrospective tools typical of 
decision support systems. Its excellent classification and pattern extraction abilities have 
been recognized and data mining has been adopted to generate of novel information 
during the construction and application of databases, especially in the evolution of 
database from the “data base” to “knowledge base”.  
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1.5.2 Data mining technologies for knowledge discovery from 
biological databases 
 
In recent years, there is an explosive growth of biological data. Understanding knowledge 
buried in the enormous amount of data deposited in different databases has become a key 
task in biomedical communities in general and the Bioinformatics community in particular. 
As a result, increasing efforts have been directed at the application of data mining in the 
knowledge discovery in various areas of biomedical research. The introduction of data 
mining in biomedical research in turn enables the development and application of the data 
mining technology in biopharmaceutical industry (in general, biopharmaceutical 
application can also be considered as a part of Bioinformatics). It is no surprise that the 
biopharmaceutical industry uses data mining to process and analyze the enormous amount 
of diverse biological information. The collected information ranges from annotated 
databases of disease profiles and molecular pathways to sequences, structure–activity 
relationships, chemical structures of combinatorial libraries of compounds, and individual 
and population clinical trial results. The use of traditional statistical data analysis methods 
faces a difficulty in solving complex relationships between various types of information. 
The problem becomes increasingly severe since more and more experimental data is 
becoming available. A similar situation is observed in biological research and the 
biotechnology industry: the Human Genome Project has sequenced billions of nucleotides; 
more people are moving into life science and more experimental data of bio-processes is 
becoming available; new application of biotechnology such as DNA microarray analysis 
is generating thousands of new data sets; chemists synthesize more and more compound 
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libraries for drug discovery. Thus, inevitably, new and powerful data analysis method is 
needed, and data mining is a useful tool for such a purpose.  
 
Because of the complexity and variety of biological events, different approaches of data 
mining have been developed and used for the specific applications. So far six types of 
approaches have been developed: 
 
Influence-based mining: complex and granular (as opposed to linear) data in large 
databases are scanned for influences between specific data sets, and this is done along 
many dimensions and in multi-table formats. These systems find applications wherever 
there are significant cause-and-effect relationships between data sets, for example, in large 
and multivariant gene expression studies, which are basis of areas such as 
pharmacogenomics [Burge et al., 1997; Iseli et al., 1999]. 
 
Affinity-based mining: large and complex data sets are analyzed across multiple 
dimensions, and the data mining system identifies data points or sets that tend to be 
grouped together. These systems differentiate themselves by providing hierarchies of 
associations and showing any underlying logical conditions or rules that account for the 
specific groupings of data. This approach is particularly useful in biological motif analysis 
whereby it is important to distinguish accidental or incidental motifs from ones with 
biological significance [Narasimhan et al., 2002; Jonassen et al., 2002]. 
 
Time delay data mining: the data set is not available immediately and in complete form, 
but is collected over time. The systems designed to handle such data look for patterns that 
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are confirmed or rejected as the data set increases and becomes more robust. This 
approach is geared towards long-term clinical trial analysis and multi-component mode of 
action studies, for example [Bellazzi et al., 1998]. 
 
Trend-based mining: the software analyzes large and complex data sets in terms of any 
changes that occur in specific data sets over time. The data sets can be user-defined or the 
system can uncover them itself. Essentially, the system reports on anything that is 
changing over time. This is especially important in cause-and-effect biological 
experiments. Screening is a good example, where responses over time to particular drugs 
or other stimuli are being collected for analysis. The software is designed specifically for 
this purpose and can identify multiple trends very efficiently [Lavrac et al., 1999]. 
 
Comparative data mining: it focuses on overlaying large and complex data sets that are 
similar to each other and compares them. This is particularly useful for all forms of 
clinical trial meta analyses where data collected at different sites over different time 
periods, and perhaps under similar but not always identical conditions, need to be 
compared. Here the emphasis is on finding dissimilarities, not similarities [Nandi et al., 
2002]. 
 
Predictive data mining: data mining alone is lacking somewhat if it is unable to also 
offer a framework for making simulations, predictions, and forecasts, based on the data 
sets it has analyzed. It combines pattern matching, influence relationships, time set 
correlations, and dissimilarity analysis to offer simulations of future data sets. One 
advantage here is that these systems are capable of incorporating entire data sets into their 
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operations, and not just samples, which significantly increase their accuracy. Predictive 
data mining is used often in clinical trial analysis and in structure–function correlations 
[Zien et al., 1999]. 
 
It should be realized that the classification of these six approaches is based on different 
situations of data analysis, other than specific algorithms of data mining. Actually, all of 
the data mining methods can be used in biological data analysis, and the approaches may 
make use of one or more of these methods at the same time. Life science is diverse; 
therefore, the application of data mining in Bioinformatics also should be diverse. The 
application of data mining is gradually accepted and applied in different areas. However, 
there are two critical factors that limit its application: a larger, well-integrated warehouse 
(databases) and a good understanding of the event that the data mining is to be applied to. 
 
In the coming chapters, we will briefly discuss the strategy of database development 
(Chapter 2). Following the strategy, two databases: Averse Drug Reaction Target 
databases DART (Chapter 3) and Kinetic Data of Biomolecular Interaction database 
KDBI (Chapter 4) were constructed. Applications based on these databases were also 
carried out to facilitate both biomedical research and drug discovery. In the final chapter 
(Chapter 5), conclusion is made to previous studies. 
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CHAPTER 2 STRATEGY OF DATABASE DEVELOPMENT 
  
 
The development of a database is a complex process of data collection, deposition and 
representation. During the entire process, different technologies are used, such as data 
mining and internet communication technologies. Generally, the database is developed in 
three stages as illustrated in Figure 2.1: database preparation, database construction, and 
database representation. The database preparation stage is the process of data preparing 
before they are uploaded into database. It is a complicated and time-consuming, which can 
be concluded in three steps: Database design, Data collection, and Data verification. 
Database construction mainly deals with the data deposition related process, especially the 
selection of database management systems and the practical construction of the database 
structure. Database representation is able to represent and redistribute the data stored in 
the database. Normally, internet communication and visualization technologies are 
intimately involved in this stage. Now we will discuss the development of database stage 
by stage. 
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2.1 Database Preparation 
2.1.1 Consideration of information content and database structure 
 
Database design is the first step and the most critical one in the database development 
process. It is important because, at this step, one must determine the content and objective 
of the database, which are the reason and the essence of the existing of database. 
Therefore, before starting the construction of the database, several questions need to be 
answered: (1) What information will the database provide? (2) Is the information new, 
particular and meaningful? (3) Is the information of database comprehensive enough? The 
first question addresses the need for the objectives of database development. A database is 
constructed for the purpose of solving or helping to solve problems. As a repository of 
specific types of information, the usefulness of a database is based on the information 
stored or interpreted. For example, SWISS_PROT protein database provides the 
comprehensive information about proteins, and PubMed stores the abstracts of biomedical 
research literature. To answer the second question, literature survey sometimes is 
necessary. While searching on-line sources or paper publications, one needs also to seek 
the answers for: Is there any particular community interested in the database? Is there any 
database providing similar information? Whether the new database provides more detailed, 
accurate, comprehensive or extra information compared with the existing databases? After 
establishing the first two prerequisites, there is one more point that needs serious 
consideration: what information will be included in the database so that the database can 
be practically useful? It is generally agreed that the modern databases should be a  
“knowledge base” rather than “data base”. Providing the novel information alone will 
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dramatically reduce the usefulness and application of the database; therefore, normally, 
relevant information is included to make the database comprehensive and applicable.  
 
Designing an efficient data structure is difficult. The difficulty comes from the large 
number of information concepts and the complex relationship between the concepts. A 
good method to properly manage diverse information is to use a flow chart. By drawing 
flow chart, distinct information concepts are allocated into different information blocks. 
For example, the information about proteins such as protein names, synonyms, gene name 
will be organized together in one block; and information about ligands such as ligand 
name, synonyms, chemical formula, etc will put together in another block called ligand 
information. For those correlated information, whether they are in the same information 
block or not, lines are used to link them directly. By using the connecting lines, the 
relationships between distinct information concepts and between different information 
blocks are properly established. The practical examples can be seen later in the 
development of databases DART and KDBI. The advantages of using flow chart for 
database architecture design include: (1) It gives an overview of database components, 
which makes later data collection relational. (2) It clearly determines the relationship 
between different information and information groups, which will facilitate later database 
construction. (3) Future modification or expansion of database will be easier by adding 
new components and building their connection with other components. (4) Integration 
with other databases constructed in the similar ways will be feasible and efficient. (5) 
Teamwork is possible by following the same data structure blueprint.  
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To conclude, database design is an important stage during the database development. 
During this stage, the significance of database is determined, and the data structure of 
database is properly drawn. 
 
2.1.2 Data collection methods 
 
The data collection is the process of gathering information from different biological 
resources. The resources include the original data of biological findings, experimental 
results, and clinical researches; the existing biological and medical databases, patents and 
even newspapers. To acquire information from various resources, different collection 
methods may apply.  The data collecting methods can be as simple as (1) manual 
collection, and complicated as (2) information retrieval (IR) and (3) text mining (TM). 
Manual collection of data is the basic method. Normally, the original and novel 
information from research is collected using this method. Some information scattered in 
different resources is difficult to extract by programs and also relies on manual work. The 
advantage of this method is that the operation on the data is free, easy, safe, and accurate. 
However, the disadvantage is also obvious, since the workload will become overwhelming 
with increasing data volumes.   
 
Some databases (named derisive databases) are generated from the existing databases 
(named parent databases). The information of these databases is closely impacted by the 
databases they are derived from. Since the data deposited in the parent databases are well 
formatted, automated parsing or generation of new data is possible. A typical derisive 
database is the protein families database Pfam, which groups the proteins according to the 
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domains contained. The domain information of Pfam is generated by studying the 
sequence similarity. The protein sequence is acquired from the protein databases 
SWISS_PROT and TrEMBL. Databases liked Pfam are not very common, as it acquires 
information from a sole parent database. Many biological databases have more than one 
data source, and cannot simply be generated using one program dealing with one data 
source. Cases will become more complicated while some novel information is hidden in 
volumes of free text resource. Therefore, multiple programs or integrated programs 
working with different data sources are desired. The process of the auto data acquirement 
from various data source is so-called data mining. Due to the fact that the majority of the 
biological information other than sequence related information comes from the medical 
literature, the data mining during the database development will focus on the text data 
mining, which is also known as text mining (TM), or knowledge discovery from text 
databases (KDT).  
  
Text mining is the process of finding interesting or useful patterns in the corpus of 
unstructured textual information. TM is not a single algorithm or technique, it is the 
combination of multidisciplinary techniques such as information retrieval (IR), 
information extraction (IE), natural language processing (NLP), statistics, and many 
techniques of data mining, e.g. rule association, decision tree, neural network, genetic 
algorithm, support vector machines.  Though there are different techniques are applied in 
the TM, generally, the framework of TM can be outlined as below [Dixon et al., 1997]: 
1. Information retrieval (IR): The first step is to locate and retrieve relevant 
documents at hand. 
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2. Information extraction (IE): The second step is to extract information from the 
selected documents retrieved in last step. 
3. Information mining: This third step is to discover the hidden pattern in the selected 
documents. 
4. Interpretation: This step is the final step to interpret the mined pattern in a natural 
language.  
 
2.1.3 Procedure of data verification 
 
A good database should present unique and useful information to the users. Above all, the 
information must be of good quality. The quality of data contains at least two elements: 
correctness and completeness. Correctness means that the information should be verified 
by experiment, clinical research, medical report, or some other recognized resource. Any 
data without verification will lower the credibility of the database. On the other hand, the 
data should be complete; incomplete information may lead to ambiguity. For example, 
muscarinic receptor subtypes distributed in different organs and have different functions. 
Incomplete statement of subtype may cause the information to be ambiguous even wrong. 
Therefore, quality control of data is critical for the construction and maintenance of a good 
database. However, it is difficult to automatically perform quality control of the databases, 
especially for biological databases. The difficulty is mainly due to: different input sources, 
incomplete information, ambiguous description, redundant information and sometimes 
typographical error. At present, there is no a standardized nomenclature system available 
for new protein identification. The designation of new proteins is normally based on the 
preference of the researchers. Because of the limited information, a protein may have 
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different names of different proteins may share the same name. It will hardly ever be 
possible to completely exclude human involvement from biological data annotation. 
Quality control is not limited to annotation or semantic checks, but also involves the 
relationships to other parts of the database [George et al., 1987]. Therefore, keeping the 
information complete, updated and consistent is very helpful to maintain the good quality 
of data. However, the complexity, incompleteness, and quickly increasing amount of the 
biological data make it difficult to keep the data updated and in good quality. One possible 
solution is to withhold suspect data until they have been corrected and supplement the 
incomplete information when more information is available. Redundancy is another 
problem often faced when constructing biological databases. It is a consequence of 
parallel acquisition of the same or highly similar data from independent sources. It also 
comes from the incompleteness of the information. The redundancy increases the burden 
of the database searching, and leads to ambiguity of data. To avoid the redundancy, it is 
necessary to validate the annotation following by similar data searching before the data is 
added to the database. 
 
2.2 Database Construction 
2.2.1 Advantages and classification of database management 
systems 
 
Database construction is a problem of how to deposit the data in the database and organize 
them in a specific way. The problem is related to later database representation, database 
searching and information retrieving. These tasks cannot be served by the database itself, 
but with the help of a database management system (DBMS). DBMS has advantages in 
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data independence and efficient access, reduced application development time, data 
integrity and security, convenient data administration, concurrent access and crash 
recovery [Ramakrishnan et al., 2002].  
 
Nowadays companies have developed different database management systems to maintain 
data deposition and application. Generally, there are four types of database systems in the 
market: the Flat File Database System, the Relational Database Management System 
(RDBMS), Objected Database Management System (ODBMS) and Object Relational 
Database Management Systems (ORDBMS).   Flat files are simply files with a table of 
information which may be separated by delimiters such as commas, colons, or semi-
colons. It was adopted in the early years of the database with limited functions and is not 
often used any more. RDBMS consists of one or several related tables of simple data in 
rows and columns. The rows correspond to records, while the columns correspond to 
attributes or fields in the records. The relationships in the databases are implied by values 
in specific fields, foreign keys in one table that match those of records in another table. 
Sometimes the intermediate table containing just the relationships is necessary. RDBMS 
mainly uses Structured Query Language (SQL) for data definition, data management, data 
access, and retrieval. ODBMS was developed to deal with complex relationship and store 
objects. ODBMS stores data in objects rather than in tables. They store attributes and class 
information, but sometimes they also store methods (behavior) in the database. Other than 
SQL, ODBMS uses an Object Query Language (OQL) as a standard language for 
communication. Data in ODBMS are controlled by using the Application Programming 
Interface (API) or both the API and OQL. Object relational or extended relational, 
database management systems is the newly emerging database technology in recent years, 
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which try to unify aspects of both the relational and object databases. ORDBMS are 
relational databases with data stored in tables, but they have a front end that converts 
objects to data and data to objects, making it seem to the application that objects are being 
stored. The comparing of these three modern DBMSs is shown in Table 2.1. Generally, 
regardless of the difference between DBMSs, database servers include both a server 
program that serves remote clients and manages the database. They may use some means 
of standard communication between client and server to allow management of the data 
such as SQL, OQL, etc. Nowadays, different commercial DBMSs have been developed by 
companies in these three database types. RDBMS is still the most popular database 
systems because of simply operation and high efficiency; however, it is believed that 
ORDBMS servers may someday overtake the RDBMS servers. Table 2.2 lists some 
representative vendors and their products. 
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Table 2.1. A Comparison of Database Management Systems 
Criteria RDBMS ORDBMS ODBMS 




Poor; programmers spend 
25% of coding time 
mapping the program 
object to the database  
Limited mostly to new 
data types Direct and extensive  
Simplicity of use 
Table structures easy to 
understand; many end-
user tools available  
Same as RDBMS, 
with some confusing 
extensions  
OK for programmers; some 
SQL access for end users  
Simplicity of 
development  
Provides independence of 
data from application, 
good for simple 
relationships  
Provides independence 
of data from 
application, good for 
simple relationships  
Objects are a natural way to 
model; can accommodate a 
wide variety of types and 
relationships  
Extensibility and 
content  None 
Limited mostly to new 
data types  
Can handle arbitrary 
complexity; users can write 
methods and on any structure  
Complex data 
relationships  Difficult to model Difficult to model  
Can handle arbitrary 
complexity; users can write 




Level of safety varies with 
vendor, must be traded 
off; achieving both 
requires extensive testing 
Level of safety varies 
with vendor, must be 
traded off; achieving 
both requires extensive 
testing  
Level of safety varies with 
vendor; most ODBMSs allow 
programmers to extend DBMS 




federated databases  
Extensive Extensive Varies with vendor; a few provide extensive support  
Product maturity Very mature  
Immature; extensions 
are new, are still being 
defined, and are 
relatively unproven  
Relatively mature 
Legacy people and 
the universality of 
SQL  
Extensive supply of tools 
and trained developers  
Can take advantages 
of RDBMS tools and 
developers  
SQL accommodated, but 




Provided by major 
RDBMS companies 
Provided by major 
RDBMS companies  
ODBMS vendors beginning to 
emulate RDBMS vendors, but 
none offers large markets to 
other ISVs  
Vendor viability 
Expected for the major 
established RDBMS 
vendors  
Expected for the major 
RDBMS vendors; 
UniSQL is struggling 
Less of an issue than it was; 
some shakeout still expected  
Source: International Data Corporation, 1997  
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Table 2.2. Database Management System Products by Vendor 
Vendor RDBMS  ORDBMS ODBMS  
Oracle Oracle 7.x  Oracle 8.x above   
Sybase System 10/11      
Informix Dynamic Server Universal Server (Illustra)   
IBM DB/2  Universal Database (DB/2 Extenders )   
UniSQL   UniSQL/X   
Unisys   OSMOS   
Computer 
Associates OpenIngres   Jasmine  
Gemstone     Gemstone 
O2     O2 
Object Design     Object Store 
Objectivity     Objectivity/DB 
Versant     Versant ODBMS
Source: International Data Corporation, 1997  
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2.2.2 Consideration of data models for database construction 
 
In addition to the database management system, the data model also play an important role 
in the database development. Data modeling is the problem of how data are stored in 
tables and how different data are connected to each other. Three data models are popular 
in database construction: flat file design, relational design, and object-oriented design as 
shown in Figure 2.2. The flat file design is the way that all records are normally stored in 
only one table where each row corresponds to one record and each column corresponds on 
one attribute (or field) as shown in Table A of Figure 2.2. Since all the annotations are 
linked as one entity, the access or search of any single field is actually performed on the 
whole entry. The advantages are easy preparation, construction, and update of database. 
However, these advantages do no longer exist when the size, dimensions (the number of 
distinctive fields/information), and relationships between different fields increase. 
Generally, flat file design is only suitable for small, low-dimensional databases.  
 
To solve the high-dimensional and complicated data management problem, relational 
design is introduced. The typical relational model is designed: different tables are created 
to store distinct information, and each table normally contains limited fields (columns) as 
shown in Table B of Figure 2.2. These tables are normally linked by unique keys.  The 
uniqueness of the keys helps to solve the complicated relationship between different 
information fields. For example, it is difficult to build the relationship between protein 
function and protein domain directly, however, they are both linked with the protein name. 
Thus introduction of a unique primary (or secondary) key of protein ID, the relationship 
between function and domain will be easily set up without error. To solve the high-
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dimensional problem and prompt searching in and between table(s), indexes are created to 
access certain field(s) of table(s). Combined with some implemented modules offered by 
management systems, the representation of data will be more convenient, fast, and flexible. 
There are many other advantages of relational model, especially when the databases 
increase in size, dimensionality, and interrelationship. There are also some points, which 
are difficult to solve by relational data modeling. For example, to solve the high 
dimensionality and interrelationship problem, many tables are created, which increases the 
workload of database initialization, upgrade, and evolution. Moreover, any operation on 
the tables may lead to the regeneration of the new indexes. 
 
Relational data models are well elaborated and widely used in academia and industries. 
They also show good performance in biological database construction. However, in many 
cases, it is helpful and necessary to describe data in terms of relationships of groups of 
records, entries or subsets. For example, the attributes of proteins such as their names, 
synonyms, gene names, physiological functions, sequence, or structure are always close-
bound and presented together, thus there it is not necessary to separate them into different 
tables. Therefore, an alternative database design, based on object-oriented principles, is 
introduced to improve the performance of RDBMS. It emphasizes the tight coupling 
between data and the set of valid operations on that data. Using this design, the database 
can be dissected into several “functional” components, for example, the protein or ligand 
prosperities, adverse drug reaction information and reference (Type C, Figure 2.2). The 
reconstruction of the data into components may slightly lower the search speed, but at the 
same time, it increases the speed of data retrieval. Most of the biological databases are not 
so large that the delay of search does not significantly affect the database performance. It 
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does not mean that object-oriented models are better than relational design or flat file 
design. The design of the data model is based on the data itself and the consideration of 
database update, database presentation, database searching, and data retrieval. A good 
database design should balance of all these factors. 
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Figure 2.2. The different data model of database 
 
Type A. The flat file model 
 
Entry ID 1 Protein 1 Function 1 … Ligand 1 … ADR 1 Reference 1 …
Entry ID 2 Protein 2 Function 1 … Ligand 2 … ADR 2 Reference n …
…. … … … … … … … …
Entry ID n Protein n Function n … Ligand n … ADR n Reference n …
 
Type B. Relational model 
 
Entry ID 1 Protein 1 
Entry ID 2 Protein 2 
… … 
Entry ID n Protein n  
Entry ID 1 Function 1 
Entry ID 2 Function 2 
… … 
Entry ID n Function n  
Entry ID 1 Ligand 1 
Entry ID 2 Ligand 2 
… … 
Entry ID n Ligand n  
Entry ID 1 ADR 1 
Entry ID 2 ADR 2 
… … 
Entry ID n ADR n  
Entry ID 1 Reference 1 
Entry ID 2 Reference 2 
… … 
Entry ID n Reference n  
Entry ID 1 … 
Entry ID 2 … 
… … 
Entry ID n …  
Type C. Object-oriented model 
 
Entry ID 1 Protein 1 Function 1 … 
Entry ID 2 Protein 2 Function 2 … 
… … … … 
Entry ID n Protein n Function n …  
Entry ID 1 Ligand 1 CAS# 1 … 
Entry ID 2 Ligand 2 CAS# 2 … 
… … … … 
Entry ID n Ligand n CAS# n …  
Entry ID 1 ADR 1 Mechanism 1 … 
Entry ID 2 ADR 2 Mechanism 2 … 
… … … … 
Entry ID n ADR n Mechanism n …  
Entry ID 1 Reference 11 Reference 12 …
Entry ID 2 Reference 21 Reference 22 …
… … … …
Entry ID n Reference n1 Reference nn … 
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2.3 Database Representation 
 
Database representation is a difficult problem since it is always dependent on the curator’s 
favorite and the solutions vary. Therefore, it is impossible to cover all the technologies in 
this thesis and only general ideas will be discussed. Considering the security and 
efficiency of the database, normally, the users don not access the database directly. Instead, 
access is provided through some applications added to the database. The connection 
between database servers and the users can be the Application Programming Interface 
(API) or the Common Gateway Interface (CGI). For the local access of database, the users 
send the request to the interface programs; the programs then interpret the request to the 
database servers; the DBMS will respond to the request and send the result back to the 
interface programs; finally, the users get their answer from the interface programs. The 
process is illustrated in Figure 2.3. Compared to the local access, the remote access 
(normally, the internet access) of database is more popular but complicated. Basically, the 
whole process of remote access is same as local access, except that the internet factor is 
included. The rough process of remote access of database is illustrated in Figure 2.4.  
Users send their requests through the web interface using a form or index; the requests 
normally are first parsed and packaged to the string suitable for internet transfer, then 
“posted” or “put” to the HTTP servers, where the requests are further interpreted; the 
interpreted requests are sent from the HTTP servers to the database servers for information 
searching and retrieval; the responds of the databases servers are feedback to the HTTP 
servers and sent back to the users’ terminals. The whole process of transferring data 
among users, HTTP servers and database servers is based on the internet protocol such as 
HTTP, TCP-IP. Sometimes, the HTTP server, and the database server share the same 
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machine, however, for security reasons, it is suggested to install these two servers on 
different machines.  The interface plays an important role in connecting the users with the 
HTTP servers. A user-friendly interface always increases database efficiency. The most 
popular interfaces include a searchable form or selection list, which is coded using the 
script languages such as PERL script, JAVA script, VB script, DELPHI, and ASP. Through 
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CHAPTER 3 DEVELOPMENT OF TOXICITY DATABASE 
DART AND ITS APPLICATION IN KNOWLEDGE 
DISCOVERY 
 
In previous chapter, we briefly introduced the strategy of database development. In this 
chapter and next chapter we will practically construct two biological databases following 
this strategy. Furthermore, applications based on these two databases will also carried out 
to facilitate both biomedical research and drug discovery. 
3.1 Development of Drug Adverse Reaction Database (DART) 
3.1.1 Collection of ADR targets related information 
 
The majority of drug adverse reaction targets information is collected from the published 
medical and biological journal papers [McEntyre et al., 2001]. The information also 
comes from drug review reports submitted by clinical doctors or published in 
pharmacology textbooks and other publicly accessible literature resources [Pumfor et al., 
1997; Wallace et al., 2000; Park et al., 2000; Rang et al., 1999; Klaassen et al., 2001; 
Baynes et al., 1999]. A target is included in DART if it has been reported that an adverse 
effect results from direct disturbance of the normal function of the target. The searching of 
ADR targets from the vast pools of medical literature resource is difficult and time-
consuming. To efficiently collect useful and updated information of ADR targets, the 
latest medical abstract packages, which are freely downloaded from PubMed literature 
database [McEntyre et al., 2001], are chosen as the major resource. The mining of ADR 
targets related information is based on the keywords mining under certain rules. The 
useful keywords are included in two separate keyword lists. One of them contains the 
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keywords concerning the adverse effects and their synonyms (Table 3.1), which are 
manually collected from the available medical literatures. The other is the distinct list of 
protein names along with their synonyms and gene names generated from SWISS_PROT 
protein database [Bairoch et al., 2000]. An engine is coded using PERL scripts to screen 
the local abstract packages. The abstracts containing ADRs targets related information are 
selected based on the following rules: 
1. The abstract will be picked up for further analysis, if it contains both a 
keyword or more from the list of the adverse effects and a keyword or more 
from the list of proteins. This rule will ensure that the abstracts contain both 
information of adverse effects and proteins.  
2. The distance between these two keywords (any combination of two keywords 
from different keywords lists) should be small enough. This rule is intended to 
check whether the coexistence of the keywords from adverse effect list and 
protein list in the abstract are related. The constraint is based on the assumption 
that two keywords are related if they appear in one complete sentence or 
adjacent sentences. The assumption is based on experience and the value of 
distance between two keywords is adjustable.  
 
The rules can be explained by formula as given below:  
keywords for adverse effects },...,,{1 21 mwwwA = ,  (3.1) 
keywords for proteins ,   (3.2) },...,,{2 ''2
'
1 mwwwA =
collection of abstracts },...,,{ 21 ntttT = ,    (3,3) 
and  denotes abstract t contains keyword w. )(wt
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if  is true, and  ),( ', kji wwt
cedisrelatedcoww kj tan_||||||min
' −≤− is true,  (3.4) 
where |w| is the absolute position in the abstract and co-related_distance is the 
average maximum distance between two co-related keywords; then the abstract 
ti will be picked out for manual analysis. 
 
The abstracts successfully selected from the abstract pools are analyzed manually, and the 
useful information of ADR targets is collected. Since the mining process is preliminary 
and manual supervision is heavily involved, evaluation of the system by accuracy is 
unnecessary. To complement the target information, the full-length papers, reports, and 
textbooks are also studied with the leads from the abstracts. 
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Heart related adverse effects 





Lipid metabolism adverse effects 
Lipodystrophy 
Mitochondrial related adverse effects













The key information extracted from literatures is the ADR targets. The targets are 
associated with diverse adverse effects, and the mechanisms leading to adverse effects are 
different. According to the mechanisms and the results of adverse effects induced by the 
drugs, the targets are mainly classified into type A ADRs-related targets, and type B 
ADRs-related targets respectively: 
 
Type A ADRs-related targets: Targets of this type are responsible for both the 
adverse effects and their therapeutic effects by interacting with the drugs. In other 
words, the adverse effects are primarily induced by affecting exactly the same 
targets as the therapeutic responses achieved by the drugs. Adverse effects induced 
by the targets of this type include all of the type A ADRs, parts of the type C, and 
type D ADRs as introduced in Chapter 1. The main mechanisms of the adverse 
effects in this category are over dose and drug-drug interactions. In most cases, 
adverse effects of this class are reversible and can be reduced by lowering the drug 
dose or, in some cases, by changing to a different drug combination. Although the 
interaction of any drug with its main therapeutic target can potentially induce type 
A ADRs, only those with well-characterized adverse effects are included in our 
database at this stage.  
 
Type B ADRs-related targets: Some adverse effects involve the interaction with 
molecules other than the expected therapeutic targets of the drugs. These 
molecules (either proteins or nucleic acids) may be the therapeutic targets of other 
drugs or key molecules in particular biological pathways. Adverse reactions in this 
category are unpredictable using the dosage or drug-drug interaction analysis. The 
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adverse effects cover all of the type B, part of type C and type D ADRs. The 
mechanisms include dysregulation of gene expression, dysregulation of ongoing 
cell activity, impairment of internal cellular maintenance and impairment of 
external cellular maintenance [Klaassen et al., 2001]. Compared to the type A-
related targets, type B targets should receive more attention, since many of type B 
adverse effects are unpredictable, serious, and even fatal. In this database, as many 
as possible type B related targets are collected.  
 
The definition of type A and type B ADR-related targets are not mutually exclusive. There 
are overlaps between them. Binding of different drugs to a target could induce either type 
A ADRs or type B ADRs. For example, Beta-1 adrenergic receptor may lead to 
dysrhythmias when activated by Beta agonists; and cardiac failure may happen while the 
receptors are inhibited by antagonists. In the database the type of ADR resulting from the 
binding of a drug to an ADR target is provided. The letter A or B in the bracket before 
each drug name indicates whether its binding to the corresponding ADR target induces 
type A or type B ADRs. 
 
In addition to ADR targets, literature-described proteins involved in adverse effect of a 
chemical are also included in our database and marked as potential ADR targets. Although 
these potential targets are not yet qualified as ADR targets, they are included in the 
database based on the expectation that they can potentially become ADR targets for new 
drugs structurally and chemically similar to the adverse effect inducing chemicals directed 
at the same target.  
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Other information in DART includes the molecular properities of each target such as its 
synonym, name of corresponding gene, physiological function, tissue distribution, and 
sub-cellular location as well as the adverse effect resulting from the binding of a drug or a 
chemical to the target. For each ADR target, the type of ADR induced by the binding of a 
drug is also given. To give a comprehensive perspective about adverse effect targets, more 
information is provided including the diseases for which each target may play an 
important role, agonists/antagonists/activators/inhibitors that bind to each target, the 
related biological pathway (enzyme only) and possible mechanisms of related adverse 
effect. Cross-links to other databases are also introduced to facilitate the access of 
information about the function, sequence, 3D structure, nomenclature, and related toxicity 
literatures of each target.  
 
3.1.2 Data structure and access of database DART 
 
As mentioned above, in total there are 20 distinct information components provided by the 
Drug Adverse Reaction Target (DART) database. Each of them is allocated in one field of 
tables in the database. The names of the fields of the concepts, their data types, and their 
sizes are listed in Table 3.2. The information components and different entries are not 
unrelated to each other. They are connected through some common items. The 
relationship map of the components and entries is shown in Map 3.1. To satisfactorily 
solve the relationship between components and entries, the Relational Database 
Management System (RDBMS), Oracle 9i database system, is chosen as our support 
system. Four tables are generated in the Oracle database: DART_TYPE, LIGAND_TYPE, 
DART_DATA, and LIGAND_DATA. DART_TYPE assigns each concept field (distinct 
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information) with one unique type ID as shown in Table 3.2. The unique type ID enables 
fast searching of respective components and easy update of the data. The detailed 
information is not stored in table DART_TYPE, but DART_DATA. The DART_DATA 
table contains three fields: the entry access number (AC), the field type ID, and the 
information. An example of such table is shown in Table 3.3. The detailed information of 
all ligands including drugs is stored in table LIGAND_TYPE and LIGAND_DATA. 
Similar to DART tables, LIGAND_TYPE defines a unique field ID for each concept of 
ligand information, and the LIGAND_DATA stores the detailed information for ligands 
associated with their field IDs. Examples of ligand tables are shown in Table 3.4 and 
Table 3.5. The data are properly formatted before they are loaded into the Oracle database. 
For the safety consideration, the data tables are not used for web access directly. The 
readable only reports are thus created in Oracle for information retrieval. To prompt the 
search process indexes are also created when necessary. 
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Table 3.2. Data types and sizes of drug adverse reaction targets 
ID Concept Data Type Size (bytes) Occurrence in an entry 
801 Protein Name Text 100 Once 
802 Protein Synonym Text 500 Null, once or more 
803 Gene Name Text 50 Null, once or more 
804 EC Number Text 20 Optional 
805 Enzyme Class Text 20 Optional 
806 SWISS_PROT AC Text 50 Once or more 
807 PDB ID Text 200 Optional 
808 Tissue Distribution Text 200 Optional 
809 Subcellular Location Text 50 Optional 
810 Protein Function Text 200 Once 
811 Reaction Equation Text 50 Optional 
812 Pathway Involved Text 50 Optional 
813 Adverse Effect Text 400 Once or more 
814 Related disease Text 100 Optional 
815 Drug (Activator) Text 500 Optional 
816 Agonists / Activators Text 1000 Once or more 
817 Drug (Inhibitor) Text 500 Optional 
818 Antagonists / Inhibitors Text 1000 Once or more 
819 Reference Text 2000 Once or more 
820 Toxicity mechanism Text 50 Optional 
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Table 3.3. The examples of Table DART_DATA 
AC ID VALUE 
5  820 Impairment of internal cellular maintenance 
… … …. 
6  801 Inducible nitric oxide synthase 
6  802 iNOS; NOS, type II; Inducible NOS; Hepatocyte NOS; HEP-NOS  
6  803 NOS2A; NOS2 
6  804 1.14.13.39 
6  805 Oxidoreductases 
6  806 P35228 
6  807 1NSI 2NSI 4NOS 
6  808 Expressed in the liver, retina, bone cells and airway epithelial cells of the lung. 
… … … 
218  819 
<<1>> Gregus Z, Klaassen CD. Mechanisms Of Toxicity. Chapter 3, Casarett And Doull¡¯s 
Toxicology, The Basic Science Of Poisons, 5th Edition.| <<2>> Zhou W, Arrabit C, Choe 
S, Slesinger PA. (2001) Mechanism Underlying Bupivacaine Inhibition Of G Protein-Gated 
Inwardly Rectifying K+ Channels. Proc Natl Acad Sci USA;98(11):6482-7 
218  820 Impairment of internal cellular maintenance 
… … … 
219  801 Glutamate [Nmda] Receptor Subunit Zata 1 
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Table 3.4. The data structure of DART ligands 
ID Concept Data Type Size (bytes) Occurrence in an entry 
901 Ligand Name Text 100 Once 
902 Ligand Synonym Text 500 Once or more 
903 CAS number Text 50 Once or more 
904 Formula Text 20 Once 
905 Class Text 20 Optional 
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Table 3.5. The examples of Table LIGAND_DATA 
AC ID VALUE 
7  905 Anti-urolithic, Antiretroviral, Drug / Therapeutic Agent, Radiation-protective agents 
… … …. 
20  901 Benzocaine 
20 902 
Anesthone; Anesthesin; Anbesol; Americaine; Aethoform; 4-Aminobenzoic acid ethyl ester; 
Benzocaine; anaesthesinum; ethyl aminobenzoate; ¦thoforme; Ethyl 4-Aminobenzoate; ethylis 
aminobenzoas; benzocaina; aethylis aminobenzoas; Cepacaine; Parathesin; Orthesin; 
Auralgan Otic 
20 903 94-09-7 
20  904 C9H11NO2 
20 905 Agricultural Chemical, Anesthetics, Skin / Eye Irritant 
… … … 
118  901 Bleomycin 
118  902 
bleomycin complex a2/b2; Bleomycin A2; Bleocin; Bleo; bleomycin hydrochloride; 
Blenoxane; bleomicina; bleomycin sulfate; bleomycin sulfate; N1-(3-
(dimethylsulfonio)propyl)bleomycinamide) (Bleomycin A2); BLM; Bleomycin 
… … … 




A user-friendly web interface is designed for the remote access of DART database using 
ASP technologies, which is shown in Figure 3.6. This database is searchable by target 
name or ligand name. It can also easily be accessed by keyword full text search such as 
adverse reaction, physiological function, or biological pathways. An exact search method 
through EC access number of enzymes, and SWISS_PROT access number is available as 
well. Searches involving any combination of these search or selection fields are also 
supported. The full text search is case insensitive and wild cards are supported. In a query, 
a user can specify a full name or any part of the name in a text field. Wild characters of '?' 
and '*' are allowed in text field. Here, '?' represents any one character and '*' represents a 
string of characters of any length. For example, input of ' cholinesterase ' in the target 
name field finds entries containing 'cholinesterase' in their name, such as Cholinesterase or 
Acetylcholinesterase. On the other hand, input of A*cholinesterase finds all the 
cholinesterase that start their names with 'A'. In this case, '*' represents 'cetyl'. 
 
The result of a typical search is illustrated in Figure 3.7. In this interface, all the toxicity 
targets that satisfy the search criteria are listed by their protein names and gene names. By 
clicking the target name, a result table specific to selected target is shown (Figure 3.8), 
where more comprehensive information about the target is given. The information may 
include: name of the target, its synonym, gene name, tissue distribution and subcellular 
location, if known, known agonists/activators/antagonists/inhibitors, possible adverse 
effect, possible toxicity mechanisms, and literature reference. For an enzyme target, its EC 
number (Enzyme Data Bank access number, http://www.expasy.org/enzyme/), 
corresponding biological pathways, and catalytic reaction described in chemical equation 
form are also provided. Additional information about a target is listed in the target 
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property item which contains the cross-links to relevant databases such as: SWISS_PROT 
database [Bairoch et al., 2000], from which the target sequence can be retrieved; The 
available 3D structure of a target can be accessed through cross-linking to the Protein Data 
Bank (PDB) database [Berman et al., 2000]. For an enzymatic target, its nomenclature can 
be obtained from cross-link to the Enzyme Data Bank. The related literature references 
can be accessed from cross-link to the relevant entries in the PubMed database [McEntyre 
et al., 2001] and TOXNET (http://toxnet.nlm.nih.gov). More detailed information on 
ligands, e.g., their synonyms, CAS register numbers, molecular formula and their possible 
function classification, is also provided, when available, by clicking the ligand name, as 
shown in Figure 3.9. 
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3.1.3 Statistics and analysis of DART 
 
At present DART database contains a total of 147 confirmed ADR protein targets reported 
in the literature. The targets distribution with respect to biochemical classes is shown in 
Figure 3.10 and Table 3.6. Enzymes form the largest group with 74 members, and this is 
followed by 37 receptors, 19 transporters and 17 other proteins. These 17 other proteins 
are structural proteins . Further analysis revealed that six classes of enzymes were found in 
this group including 27 hydrolases, 4 isomerases, 2 ligases, 27 oxidoreductases, 9 
transferases, and 5 lyases. These enzymes are distributed in 24 of 61 enzyme sub-families, 
among which subfamilie of oxidoreductases (with EC1.14.-.-), acting on paired donors 
with incorporation or reduction of molecular oxygen, shows high probability (17 out of 74) 
to be the ADR targets. The high concentration of ADR targets in the EC1.14.-.- sub-
family is due to the presence of Cytochrome P450 family in ADRs. Cytochrome P450 
(CYP) enzymes often play a dominant role in target tissue metabolic activation of 
xenobiotic compounds. They may also determine drug efficacy and influence the tissue 
burden of foreign chemicals or bioavailability of therapeutic agents. The competition 
binding or inhibition of P450s will cause the aberrant metabolism of drugs. Incomplete 
metabolism of drugs typically leads to the deposition of drugs or their metabolites in 
organisms resulting in the toxicity effects. Similar phenomenon is observed in the receptor 
group. As shown in Table 3.6, 20 out of 37 receptors belong to the G-protein coupled 
receptor family. G protein-coupled receptors (GPCRs) constitute the largest single class of 
receptors and are responsible for mediating much of intracellular mammalian signaling. 
Indeed, over 40 percent of the pharmacological targets being evaluated by drug companies 
are related to G protein-coupled receptors [Benovic et al., 1999]. Thus, any improper 
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interaction between GPCRs and drugs may cause inappropriate performance of 
physiological functions resulting in toxic effects. It is noted that, of all these ADR targets, 
36 proteins are also found to be therapeutic targets, which likely leads to type A adverse 
drug effects when their therapeutic performance is significantly affected.  
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Figure 3.10 The distribution of drug adverse reaction targets 
 
  




















Table 3.6. The distribution of ADR target proteins 
 
 
Proteins Family Definition Quantity Total 
EC 1.1 Oxidoreductases, acting on the CH-OH group of donors 2 
EC 1.10 Oxidoreductases, acting on diphenols and related substances as donors 1 
EC 1.14 Oxidoreductases, acting on paired donors, with incorporation or reduction of molecular oxygen 17 
EC 1.3 Oxidoreductases, acting on the CH-CH group of donors 1 
EC 1.4 Oxidoreductases, acting on the CH-NH2 group of donors 2 
EC 1.5 Oxidoreductases, acting on the CH-NH group of donors 1 
EC 1.6 Oxidoreductases, acting on NADH or NADPH 3 
EC 1.9 Oxidoreductases, acting on a heme group of donors 1 
EC 2.1 Transferases, transferring One-Carbon Groups 1 
EC 2.3 Transferases, acyltransferases 1 
EC 2.6 Transferases, transferring Nitrogenous Groups 2 
EC 2.7 Transferases, transferring Phosphorus-Containing Groups 5 
EC 3.1 Hydrolases, acting on Ester Bonds 9 
EC 3.2 Hydrolases, glycosylases 5 
EC 3.3 Hydrolases, acting on Ether Bonds 1 
EC 3.4 Hydrolases, acting on peptide bonds (Peptidases) 8 
EC 3.5 Hydrolases, acting on Carbon-Nitrogen Bonds, other than Peptide Bonds 2 
EC 3.6 Hydrolases, acting on Acid Anhydrides 4 
EC 4.1 Carbon-Carbon Lyases 1 
EC 4.2 Carbon-Oxygen Lyases 2 
EC 5.1 Isomerases, Racemases and Epimerases 1 
EC 5.2 Cis-trans-Isomerases 1 
EC 5.99 Other Isomerases 3 
Enzyme 
EC 6.3 Ligases, forming Carbon-Nitrogen Bonds 2 
74 
G protein coupled receptor 20 
Nuclear receptor 6 Receptor 
Others 11 
37 
Transporter 19 19 
Others 17 17 
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3.2 Knowledge Discovery from DART: Prediction of ADR 
Targets Based on Protein Primary Sequence 
3.2.1 The need of computational prediction of ADR targets 
 
There are a total of 147 drug adverse reaction targets collected in DART database at 
present. These targets cover different classes of proteins including enzymes, receptors, 
transporters, and other proteins, as analyzed previously. It will be useful for facilitating the 
mechanistic understanding of ADRs if all of these different ADR targets can be identified. 
Traditionally, ADR targets are identified through studies of patient response to marketed 
drugs. The identifying process is unsupervised and mainly based subjective evaluation of 
patients. The toxicity results from animal experimental are often not transferable to 
humans. It would be of great advantage if those targets could be identified with limited 
experiments, or even without any experiment, on animals or patients. Sequence analysis is 
considered a feasible approach for protein function prediction. It is based on the empirical 
rule that proteins with homologous sequences will fold into similar 3D structure; proteins 
with similar structures may perform similar functions. According to this rule proteins with 
high similarity in sequence alignment predicted with BLAST or FASTA way have a similar 
function. However, there are exceptions. For example, Glycolate oxidase and IPP 
isomerase are homologous in sequence alignment, but belong to different enzyme families 
and behave different functions. Furthermore, classification of ADR targets concerns not 
only the functions of the proteins, but also their behavior in the biological pathways. 
Those information cannot be obtained through sequence alignment, thus sequence 
alignment alone is not sufficient for the classification of ADR targets. Other possible 
approaches include the structure-function relationship studies, which are limited by the 
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availability of 3D structures of proteins; biological pathways studies, which are often 
incomplete. Therefore, in this study we propose a new approach of using Support Vector 
Machines (SVMs) algorithm to classify ADR-related proteins. 
 
3.2.2 Procedure of ADR-related prediction using SVM classifier 
 
SVMs are principally a two-class classifier. After proper construction of the model of the 
SVMs using the known example data, the correct classification will be given for the 
unknown data. One can ignore the performance of the vectors (here, the protein features) 
in the respective feature spaces. Detailed description of SVM algorithm can be found in 
the attached Appendix A.  
 
The application of SVMs to the classification of ADR targets starts from the assumption 
that all proteins can be grouped into two classes: the ADR targets (positive data) and non-
ADR targets (negative data). The input is the primary sequences of proteins and the output 
is the respective classes of the proteins. The protein pools came from the SWISS_PROT 
database, which were divided into three sets of data: Training data, Testing data, and 
Independent data. All of these three data sets are composed of both positive data and 
negative data. The training data is used to construct the model; testing data is to examine 
the model and optimize it; and the independent data can be used for the model evaluation. 
The design of the datasets is based on the consideration of both the quantities and the 
qualities of positive and negative data. The selection of positive data is obvious, which 
include the complete list of the proteins in the DART database. However, the quantity of 
147 ADR target proteins is too limited to be divided for training, testing and evaluation of 
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SVM model. Considering the same proteins in different species may have the same 
functions, it will be helpful to expand the positive data set by including target proteins 
from different species. Another advantage of data expansion is that the training datasets 
and testing datasets will cover all the known ADR targets for machine learning, thus likely 
increases the accuracy of the classification. To improve the accuracy of positive prediction 
and well represent true ADR targets, the incomplete proteins such as fragment or partial 
sequence, as well as the pre-defined proteins such as the hypothetical proteins, are filtered 
out of the positive data pools.  
 
The selection of negative samples is more complicated and however critical: 
1. Generate the positive data pools. Collect all target-related proteins (positive data), 
which include both the ADR targets in DART and same proteins from different 
species. Searching the latest version of SWISS_PROT knowledge base, a list of 
SWISS_PROT access number (AC) for the positive data is generated.  
2. Retrieve the family information of the positive data. Domain families of positive 
data are generated by matching SWISS_PROT ACs of positive data in the Protein 
Families Database Pfam. Any Pfam family containing one of the positive 
SWISS_PROT AC is considered as positive pfam family.  
3. Generate the negative data pools. The generation of negative families is 
facilitated by removal of all positive Pfam families from the Pfam database. This 
process can be conducted by using the Pfam family ID. The proteins in the 
remaining Pfam families will constitute the negative data pools. 
4. Generate the negative data. The negative datasets are randomly picked from the 
negative data pools following the rules that the seed samples of all the negative 
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Pfam families must be present. The number of the seeds for each negative Pfam 
family is determined by the size of the negative datasets, which is normally 
balanced with the positive datasets. Three sets of negative data are thus created 
for training, testing and independent evaluation. 
 
The positive and negative datasets of protein sequences are now ready for SVM learning 
process. Every protein sequence can be represented by specific feature vectors assembled 
from encoded representations of tabulated residue properties including amino acid 
composition, hydrophobicity, normalized Van der Waals volume, polarity, polarizability, 
charge, surface tension, secondary structure, and solvent accessibility for each residue in 
the sequence and so on. The constructed feature vectors of both positive samples and 
negative samples are then loaded into SVM classification system for training in order to 
identify features that separate positive and negative samples. The SVMPROT system is 
coded by Dr. Cai [Cai et al., 2003] for protein family classification. After computing the 
model for about 24 hours for our study, the event-dependent parameters of SVMPROT 
system are optimized. The well-normalized learning system is now able to classify a new 
protein sequence into either the positive group (ADR targets) or the negative group (non-
ADR targets). 
 
As in the case of all discriminative methods [Baldi et al., 2000], the performance of SVM 
classification can be measured by the quantity of true positives (TP), true negatives (TN), 
false positives (FP), false negatives (FN), and the overall accuracy (Q) given below: 
FNFPTNTP
TNTPQ +++
+=        (3.5) 
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Nprecision =         (3.7) 
Where recall represents the number of correct classification Ncorrect returned by the system 
as a ratio of the total number of relevant classification (or facts) Nresponse. Precision is the 
ratio of the number of correct answers over the total number of answers Nkey. 
 
3.2.3 Prediction results for ADR targets based on protein sequence 
 
The results for the ADR targets prediction are given in Table 3.7. All the computed TP, 
TN, FP, and FN for the test sets and independent evaluation sets are given in the table. 
There are 1013 positive protein entries and 2521 negative protein entries used to construct 
the classification model. Among the 683 positive proteins used for testing model, only 3 
of them are incorrectly classified, and there is no incorrect classification out of 2426 
negative data during the optimization of model. In an independent evaluation, about 
96.8% (735 out of 759) of positive protein sequences are correctly classified into the ADR 
targets, while 87.3% (1993 out of 2281) of negative proteins are correctly classified into 
the class of non-ADR targets. The average overall prediction accuracy Q is 89.7% for 
3040 independent protein entries.  
 
To determine whether or not the prediction error is caused by sequence-related problems 
such as fragmentation, incomplete chains, or mutations, amino acid sequences of wrongly 
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predicted proteins are examined. These sequence-related problems do NOT appear to be a 
significant factor, as they only compose less than 10% of false positive predictions. It is 
also found that no significant (less than 5%) sequence-related problems exist in false 
negative predictions. Several other factors may affect the prediction accuracy. One is the 
uncertainty of the protein definition in the SWISS_PROT. Notably about 68.8% of false 
positive predicted proteins are hypothetical proteins. Those proteins still need further 
verification and study for their physiological functions. On the contrast, hypothetical 
proteins were not included in the positive samples. The different treatment of the positive 
and negative data set is under the consideration for protecting the feature completeness of 
positive data and diversity of negative data. Another possible reason is the diversity of 
protein samples, which could be the main reason for the false negative prediction. It is 
likely that not all possible types of proteins are adequately represented in training and 
testing datasets. This can also be improved along with the availability of more protein data. 
 
To further verify the accuracy of the computational prediction of ADR targets, randomly 
selected proteins are used for SVMPROT prediction. It is satisfying that the overall 
prediction accuracy Q is as high as 93.3%.  The partial predicted results are listed in Table 
3.8. The physiological functions of proteins are provided to help understanding of their 
possible roles in the normal physiological activities and etiology. The prediction is also 
supported by possible (indirect or incomplete) experimental/clinical results. More research 
is needed to fully confirm our prediction.  
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Table 3.7. Results of ADR target proteins predicted by SVMPROT 
 
Training set Testing set* Independent evaluation set 
Positive Negative Positive Negative Positive Negative Q 
TP FN TN FP TP FN TN FP 




Q: overall accuracy; 
TP: true positives 
FN: false negatives 
TN: true negatives 
FP: false positives 
 
* The testing results is demonstrated with 
Recall = 99.6% 
Precision = 100% 
 
CHAPTER 3 83
Table 3.8. Comparing physiological functions of predicted ADR targets with their possible 
adverse effects 
 





Involved in an NADPH-dependent electron 
transport pathway in liver microsomes. Known to 
oxidize a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. 
Tardive dyskinesia Positive 
P-Glycoprotein 1 
Responsible for decreased drug accumulation in 
multidrug-resistant cells. Protection of intestine 
mucosa layer. Energy-dependent efflux pump. 
Inhibition causes lower 
oral bio-availability of 




Involved in the regulation of eukaryotic gene 
expression. Found to affect cellular proliferation 
and differentiation in target tissues. 
Cytotoxicity, Cell death Positive 
Cytochrome 
P450 2D6 
Responsible for the metabolism of many drugs and 
environmental chemicals that it oxidizes. It is 
involved in the metabolism of drugs such as 









Pyruvate kinase is the final regulatory point in the 
catabolic Embden-Meyerhoff-Parnas pathway, 
which controls the carbon flux of glycolytic 
intermediates and regulates the level of ATP in the 
cell. 
Emolytic anemia Positive 
Tyrosine 
Aminotransferase 
Known to transaminate dicarboxylic as well as 
aromatic amino acids. 
Eye and skin lesion, 
Neurological problems Positive 
Adenylosuccinate
Synthetase 
 Involved in the de novo pathway of purine 
nucleotide biosynthesis. 
Toxicologic effects of 
L-alanosine Positive 
Heat Shock-
Related 70 Kda 
Protein 2 
Known to stabilize preexistent proteins against 
aggregation and mediate the folding of newly 
translated polypeptides in the cytosol as well as 
within organelles, in cooperation with other 
chaperones. Found to provide a driving force for 
protein translocation in mitochondria and the 
endoplasmic reticulum. Involved in signal 
transduction pathways in cooperation with hsp90. 
Known to participate in all these processes through 
their ability to recognize nonnative conformations 
of other proteins. Found to bind extended peptide 
segments with a net hydrophobic character 
exposed by polypeptides during translation and 










Known to play an important role in controlling 
membrane potential and contractility of urinary 
bladder smooth muscle (UBSM). 
Convulsion, spasm Negative
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3.3 Application of DART: Computational Evaluation of Drug 
Safety 
3.3.1 The need for the development of computer-aided drug safety 
evaluation tools 
 
Drug discovery process is complex, costly and time-consuming. The process is also 
known to be risky during the pre-clinical and clinical testing phases due to the potential 
ADR effects of compounds. In the pre-clinical phase, toxicity experiments in animal and 
cells (mainly the drug metabolism enzymes P450s) are standard methods for the drug 
safety evaluation. However, the toxicity results of a drug found in animal experiments do 
not always agree with its adverse effects in human; and enzyme analysis is focused on the 
potential adverse effects induced by the drug-drug interaction. In the clinical testing 
phases, the knowledge of ADRs mainly comes from the clinical reports of healthcare 
professionals submitted to the ADRs reporting systems. Such systems do provide accurate 
ADR information of potential drugs; unfortunately, the information is based on individual 
patient evaluation. Therefore, an efficient and safe method for drug safety evaluation is 
desired. 
 
Computer-aided assessment of potential ADR of investigational drugs has received 
increasing attention in recent years. In this work, a specific computer method is explored 
for identification of the putative ADR-causing target proteins. The approach involves the 
use of a protein-ligand software and a supporting database. The computer program 
adopted here is the inverse docking algorithm (INVODOCK) developed by Chen [Chen, 
2001], which is able to automatically predict the possibility of docking a ligand into a 
protein. The supporting database is the target database, the Drug Adverse Reaction Target 
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database (DART), which collects the literature-confirmed drug adverse reaction target 
proteins. 
 
3.3.2 A drug safety prediction method: INVODOCK and its algorithm 
 
INVODOCK is a ligand-protein inverse docking algorithm, which is able to facilitate 
computer-automated inverse docking search for finding putative protein targets of a small 
molecule [Chen et al., 2001]. The proper application of the software requires a protein 
cavity database developed from relevant protein entries in PDB. The database contains 
models of individual cavity in each protein. A cavity model is a cluster of overlapping 
spheres that fill-up that cavity [Kuntz et al., 1982]. A drug is flexibly docked into the 
cavity by a procedure involving multiple conformer shape-matching alignment of the 
molecule to the cavity. This is followed by the molecular-mechanics torsion optimization 
and energy minimization on both the ligand and the binding region of the protein. Putative 
protein targets are selected based on a new scoring scheme that performs binding 
competitive analysis in addition to the evaluation of molecular mechanics ligand-protein 
interaction energy. More detailed description of the core docking algorithm is provided in 
following. 
 
Docking is a term used for computational schemes that attempt to find the “best” fit in the 
binding of two molecules: a protein and a ligand. The molecular docking problem can be 
defined as follows: Given the atomic coordinates of two molecules, predict their “correct” 
bound association. In figurative way, the docking problem can be described as the 
relationship between “lock” and “key”: how to put the suitable “key” into the suitable 
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“lock”. The early docking algorithms were based mainly on geometric criteria [Kuntz et 
al., 1982], although a few energy-based algorithms were also developed [Goodsell et al., 
1996]. Generally, there are three key ingredients in the docking: (1) representation of the 
system, (2) conformational space search, and (3) ranking of potential solutions [Halperin, 
2002]. Representation of the system is the question of how to define a protein surface. The 
basic description of the protein (or ligand) surface is the atomic representation of exposed 
residues. However, this explicit simulation is usually based on real potential energy 
functions, which require significant computer time for modeling complex binding. 
Different mathematical models have been built to simplify the system by assuming one or 
both of the molecules in the docking system are rigid. Considering this approximation, the 
computational procedure inherent to docking can be classified into three levels: (1) Rigid 
body docking, a highly simplistic model, which treat the two molecule as rigid solid 
bodies; (2) Semi-flexible docking, which consider one of the molecule, normally the small 
ligand, flexible and the other molecule rigid; (3) Flexible docking, which both molecules 
are regarded as flexible, although the flexibility is usually limited.  
 
The docking procedure induces energy changes and conformational changes. The 
conformational changes may be due to the motion of backbone or side chain of the 
molecules, especially at the binding site, solvation, electrostatics, or van der Waals force. 
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Etotal is the total energy of the molecule; ∑ −
bonds
eqr rrK
2)(  is the energy of bond stretches, 
where Kr is the force constant of bond stretches, r is the length of bond and req is the 
length of bonds at equilibrium position. ∑ −
angles
eqK
2)( θθθ  is the energy of angles blending, 
where Kθ is the force constant of bond angles, θ is the angle of bond bending and θ eq is the 






γφφ  is the energy of bond 
torsion, where  is the energy cost associated with the deformation, is the value of the 
dihedral angle in our structure, n (the multiplicity) is the number of energy minima that 
exist for the dihedral angle, γ is used to determine where the dihedral angle passes through 













4 σσ  is van der Waals interaction energy for 
pairs of non-bonded atoms, where σ is the distance at which the Lennard-Jones interaction 
energy is zero, ∈ is the minimum energy of the Lennard-Jones potential, R is distance 
between atoms. ∑
−bondnon DR
qq 21  is the charge interaction energy for non-bonded atoms, where 
q1 and q2 are the partial charges on the atoms, D is the dielectric constant.  
 
There are numerous ways for two molecules to interact, and the number of possibilities 
grows exponentially with the size of components [Shoichet et al., 1992]. Hence, docking 
is actually the problem of searching conformational space, which will locate the most 
stable state (global minimum) in the energy landscape in a rugged funnel shape. The 
solutions can be obtained by two essentially different approaches: (1) full solution space 
search, which scans the entire solution space in a predefined systematic manner; (2) 
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gradual guided progression through solution space, which scans only part of the solution 
space in a partially random and partially criteria-guided manner or generates fitting 
solution [Halperin, 2002]. The solutions for the conformational space search are assessed 
by some energy functions in a coarse manner (e.g. hinge-bending algorithms [Sandak et 
al., 1998]) or more rigorously (e.g. Monte Carlo [McMartin et al., 1997], molecular 
dynamics [Wang et al., 1999], genetic algorithm [Politowska et al., 2002] etc). Whichever 
algorithm is chosen, the objective is to find the energy minimum state of docking. 
 
There are different algorithms available for docking that can produce an immense number 
of solutions for the conformational space search. Thus, a scoring scheme is desired to 
discriminate between the “correct” native solutions and other low-energy complex 
conformations. Theoretically, free-energy simulation can be applied, however, it is not 
practical due to its computational requirements. The alternative solutions of the scoring 
problems have been succeed by, for example, evaluating the similarity to a reference 
structure [Fradera et al., 2000]. At present, there is no efficient method available for 
reliable discrimination between correct solutions and false positives generated by 
predictive docking algorithms [Norel et al., 1999].  
 
3.3.3 Procedure of identifying potential ADRs targets of 11 marketed 
anti-HIV drugs 
 
The computational study is carried out for the prediction of potential ADR target of 11 
marketed AIDS drugs. These drugs have been used in the treatment of AIDS by binding to 
two different therapeutic targets. They are of different structural types including HIV 
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protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse 
transcriptase inhibitor and nucleoside analogs [Table 3.9]. The 3D structures of these 
drugs are downloaded on-line and some of them are shown in Figure 3.11.  
 
The prediction of ADR targets by INVODOCK is carried out on UNIX machine with the 
CPU speed of 700MHz and memory of 128Mbytes. The INVODOCK is initialized by 
transforming the respective 3D structures of ligands (drugs) into “.pdb” format. The 
species of cavity database (PDB protein database) is selected to constrain the search scope 
to reduce the computational burden and increase the relevance of the search. In this study, 
only the mammalian and human PDB proteins are chosen for docking. The selection is 
based on the objective of studying the possible toxicity targets in human. The inclusion of 
mammalian proteins is supplements limited human PDB proteins, whose structure are 
evolutionarily close to each other. INVODOCK docks each ligand to multiple proteins. 
The time of calculation is varied from one week to two weeks depend on the ligand sizes. 
The small ligands may take longer time to search all the possible cavities because they are 
more possible to be docked into protein cavities compared to larger ligands. 
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mechanism* Observed side-effects 
Delavirdine Rescriptor NNRTI Severe rashes and skin reactions are common 
Nevirapine Viramune  NNRTI Severe rashes and skin reactions are common 
Efavirenz  Sustiva NNRTI Dizziness, headache, insomnia, inability to concentrate, and 




NA The most common side effects are gastrointestinal: upset 
stomach, nausea, vomiting. A more serious side effect 
neutropenia, a blood disorder, can occur. Pancreatitis or 
inflammation of the pancreas can also occur, but is more 
common in children.  
Stavudine D4H, Zerit NRTI Peripheral neuropathy, numbness, tingling, or pains in hands or 
feet are common. 
Abacavir Ziagen NRTI The common side effects are potential hypersensitivity reaction, 
fever, stomach and bowel symptoms, general malaise, and 
sometimes rash. If resume the Abacavir after stopping, the 
hypersensitivity can occur quicker and more severely. 
Amprenavir Agenerase PI The most common adverse effects are nausea, diarrhea, 
vomiting, and oral rashes. Elevated blood glucose levels and 
altered body fat distribution are also reported. 
Indinavir Crixivan PI It is generally well tolerated, and sometimes may cause mild 
elevation of bilirubin, and some people may get kidney stones.
Nelfinavir Viracept PI Nelfinavir is generally well tolerated. Diarrhea, nausea, 
abdominal pain and elevated blood glucose levels can occur 
sometimes.  
Ritonavir Norvir  PI Ritonavir can cause nausea, vomiting, diarrhea, a feeling of 
numbness, altered tastes, and a rise in cholesterol levels, 
however the side effects can be reduced when drugs are taken 
with food. 
Saquinavir Invirase PI Saquinavir is generally well tolerated. Diarrhea, nausea, and 
abdominal pain sometimes can occur. 
 
* NNRTI: non-nucleoside reverse transcriptase inhibitor;  
NRTI: nucleoside reverse transcriptase inhibitor;  
NA: nucleoside analogs;  
PI: protease inhibitor. 
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3.3.4 Prediction results of anti-HIV drugs and analysis 
The program INVODOCK produces a list of docked proteins, file “ligand-docklist” (the 
“ligand” is the names the respective studying drugs) after all the cavity searching finished. 
This “ligand-docklist” file lists all the proteins into which the studied ligand can be 
docked, along with their PDB IDs. These proteins are considered as the potential target 
proteins of the corresponding ligand. Moreover, the individual docking results for each 
protein are saved in “.pdb” format as well (Figure 3.12).  
 
The putative targets of investigational drugs predicted by INVODOCK are summarized in 
Table 3.8, which is listed in quantities of human targets against that of all studied species 
(mammalians). It is noted that if investigational drug can be docked into more putative 
targets (both the human targets and total targets), it may induce more dangerous or various 
the drug side effects. The conclusion is also supported by examination of the number of 
the predicted ADR targets. The identification of ADR targets is by matching the putative 
target proteins with proteins in the ADR target database DART.  The matched of ADR 
targets are also listed in Table 3.10. It is found that comparing to the non-nucleoside 
reverse transcriptase inhibitors (NNRTI) and nucleoside reverse transcriptase inhibitors 
(NRTI), the HIV protease inhibitors (PI) have few number of ADR targets. This finding 
agrees with the clinical observation that protease inhibitors have less serious side effects 
such as mitochondrial toxicity-related side effects, comparing to other types of AIDS 
drugs. Therefore, PIs are commonly used for the treatment of first-line therapy or naïve 
therapy since their first use in 1996 [Cvetkovic et al., 2003; Joly et al., 2002].  
 
CHAPTER 3 93
To confirm that the predicted ADR targets are meaningful and accurate, two comparisons 
are made. First, whether the side effects induced by the predicted ADR targets agree with 
the clinical side effects of drugs, which are predicted to be docked into the target proteins. 
The example of this comparison is shown as Table 3.11. The protein DNA polymerase 
beta is suggested to be the putative targets of 9 AIDS drugs. Our result indicates that 6 out 
of 9 drugs show the kind of adverse side effects expected for the binding to DNA 
polymerase beta (+), one has side effects probably related to this protein (+/-), and the 
remaining two drugs are not reported to produce effects related to this protein (-). The near 
80% prediction accuracy demonstrates that the computational prediction of toxicity by 
INVDOCK program is feasible. The binding of some AIDS drugs such as Abacavir 
[Kakuda et al., 2000], Lamivudine [Hart et al., 1992; Kakuda et al., 2000], Stavudine 
[Stammberger et al., 1989; Kakuda et al., 2000] with DNA polymerase beta has been 
confirmed by experimental studies.  
 
The efficiency of the prediction is also studied by comparison of the clinical side effects of 
studied drugs with the side effects induced by corresponding putative ADR targets. As 
shown in Table 3.12, there are 4 proteins predicted by INVODOCK to be the putative 
ADR targets of Abacavir, among which DNA polymerase beta contribute the 
gastrointestinal side effects and the neuropathy such as hypersensitivity, and DNA 
topoisomerase I may be related to the fever, general malaise, and rash.  It is not reported 
that Abacavir causes kidney related disease or Lipodystrophy, which are induced by 
FK506-binding protein 1A and Sterol regulatory element binding protein-1 respectively. 
The putative protein targets basically explain the clinical side effects of the studying drugs, 
however, some possible side effects induced by the predicted putative ADR targets have 
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not yet been found clinically. The reason could be either the over-prediction of the 
program or the inadequate clinical information.  
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DNA polymerase beta 
DNA topoisomerase I 
FK506-binding protein 1A 
Abacavir 70/136 4 
Sterol regulatory element binding protein-1 
DNA polymerase beta 
Amprenavir 15/30 2 
DNA topoisomerase I 
DNA polymerase beta 
Delavirdine 22/45 2 
DNA topoisomerase I 
DNA polymerase beta 
DNA topoisomerase I 
Insulin 
Efavirenz 47/92 4 
Sterol regulatory element binding protein-1 
Indinavir 2/3 1 DNA polymerase beta 
DNA polymerase beta 
DNA topoisomerase I 
FK506-binding protein 1A 
Insulin 
Macrophage migration inhibitory factor 
Lamivudine 70/182 6 
Sterol regulatory element binding protein-1 
Ritonavir 1/1 0 - 
Saquinavir 3/6 0 - 
Nelfinavir 17/22 1 DNA polymerase beta 
DNA polymerase beta 
DNA topoisomerase I Nevirapine 72/131 3 
Sterol regulatory element binding protein-1 
DNA polymerase beta 
DNA topoisomerase I 
Insulin 
Macrophage migration inhibitory factor 
Stavudine 66/125 5 
Sterol regulatory element binding protein-1 
 
* Quantities of target proteins predicted by INVODOCK, shown in human proteins/total proteins.  
** The INVODOCK-predicted ADR target proteins found in DART database. 
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Table 3.11. Relationship between the predicted ADR target protein of different AIDs 




Side effect induced Drug Observed drug side effect Correlation*
Abacavir Hypersensitivity reaction, fever, 
stomach and bowel symptoms, general 
malaise, and rash. 
+ 
Amprenavir Nausea, diarrhea, vomiting, oral rashes, 
elevated blood glucose levels and 
altered body fat distribution. 
+ 
Delavirdine Severe rashes and skin reactions. - 
Efavirenz Dizziness, headache, insomnia, inability 
to concentrate, rash, vivid dreams, 
nightmares, and hallucinations. 
+ 
Indinavir Mild elevation of bilirubin, and kidney 
stones. 
+/- 
Lamivudine Nausea, diarrhea, vomiting, oral rashes, 
elevated blood glucose levels and 
altered body fat distribution. 
+ 
Nelfinavir Diarrhea, nausea, abdominal pain and 
elevated blood glucose levels 
+ 






pain, adverse GI effects 
such as nausea and 
vomiting 
Stavudine Peripheral neuropathy, numbness, 
tingling, or pain in hands or feet. 
+ 
 
*The co-relation between the predicted side effect of the ADR target proteins and clinical observed side 
effect of the drugs: 
 
“+” means correlated; 
“-” means non-correlated; 
“+/-” means uncertain relationship; 
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Table 3.12. Relationship between the different predicted ADR targets of the AIDs drug 
and its corresponding observed side effects 
 
 
Drugs Observed Side effect Name Protein Side 
effect 
Correlation*
FK506-binding protein 1A Nephrotoxicity - 
DNA topoisomerase I Cytotoxicity and 
DNA lesion. +/- 




adverse GI effects 
such as nausea and 
vomiting. 
+ Abacavir 
The common side effects are 
potential hypersensitivity 
reaction, fever, stomach and 
bowel symptoms, general 
malaise, and sometimes 
rash. If resume the Abacavir 
after stopping, the 
hypersensitivity can occur 











CHAPTER 4 DEVELOPMENT OF KINETIC DATABASE 
KDBI AND ITS APPLICATION IN KNOWLEDGE 
DISCOVERY 
 
4.1 Development of Kinetic Data of Bio-molecular Interactions 
(KDBI) 
4.1.1 Collection of kinetic information 
 
The majority of the information in Kinetic Data of Bio-molecular Interactions database 
(KDBI) is manually collected from the published medical literature manually. The 
information includes experimentally determined kinetic data for protein-protein, protein-
DNA, protein-RNA, protein-ligand, DNA-ligand, and RNA-ligand interactions. KDBI 
provides detailed description about binding or reaction events, participating molecules, 
binding or reaction equations, kinetic data, and related references. A variety of molecular 
descriptions are also provided which include names of molecules, synonyms, 
SWISS_PROT AC for a protein or CAS number for a small molecule ligand, molecular 
formula, classification, protein function and tissue distribution. The kinetic data is 
presented as one or a combination of kinetic quantities as given in the literature of a 
particular event. These quantities include association/dissociation rate constant, on/off rate 
constant, first/second/third/… order rate constant, catalytic rate constant, equilibrium 
association/dissociation constant, inhibition constant, and binding affinity constant.  
 
4.1.2 Data structure and access of database KDBI 
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There are 20 distinct information components provided by the database of KDBI. Each 
component is allocated in one field of table in the database. The data structure of the 
database such as the fields, their data types, their sizes and their occurrence in one entry is 
listed in Table 4.1. The distinct information components and different entries are cross-
related to each other. For example, one protein can interact with different ligands and one 
ligand can also interact with different proteins vice versa. The relationship map of the 
concepts and entries is shown in Map 4.1. To properly organize the complicated 
relationship between the molecules, the unique molecule ID is assigned to each distinct 
molecule. Two specific characters are prefixed in the unique molecule ID to differentiate 
the molecule types, following by the five numbers for different molecules. The 
identification of molecules is defined as shown in Table 4.2. The properly formatted data 
is loaded into the supporting database system, Oracle 9i database system, which is the 
Relational Database Management System (RDBMS). Four tables are generated in the 
Oracle database to solve the complicated relationships: KDBI_TYPE, MOL_TYPE, 
KDBI_DATA, and MOL_DATA. KDBI_TYPE assigns a unique field ID for each of the 
distinct kinetic information, as shown in Table 4.1. The detailed content of kinetic 
information is stored in table KDBI_DATA. The KDBI_DATA table contains three fields: 
the entry access number (AC), the field ID, and the respective kinetic contents. The 
example of the table is shown at Table 4.3. The detailed information of bio-molecules and 
their data structure is defined and stored in table MOL_TYPE and MOL_DATA 
respectively, which MOL_TYPE defines the unique field IDs for each concept of ligands 
information, and the MOL_DATA stores the detailed information of proteins and ligands 
associated with their field IDs. The examples of molecule tables are shown in Table 4.4 
and Table 4.5. The data are analyzed and formatted before they are loaded into the Oracle 
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database. For safety consideration, the data tables are not directly accessed by web users. 
Instead, the readable-only reports are created in Oracle for information retrieval. To 
enable fast-speed for searching, indexes are also created when necessary. 
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Table 4.1. The data structure of Table KDBI_TYPE 
 
 
ID Concept Data Type Size (bytes) Occurrence in an entry 
701 Molecule ID one Text 10 Once 
702 Molecule ID two Text 10 Null or once 
703 BioEvent Text 100 Once 
704 Reaction Text 200 Null, once or more 
705 Kinetic Item Text 20 Once 
706 Kinetic value Text 20 Once 
707 Kinetic unit Text 20 Once 
708 Reference Text 200 Once 
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Table 4.2. The definition of molecule ID 
 
 
Prefix Molecule type 
PN Protein 
PC Protein Complex 
NA Nucleic Acids 
LG Ligand 
IN Ion 




Table 4.3. The example of KDBI_DATA 
 
 
AC TYPE VALUE 
… … … 
5 701 PN00091 
… … … 
21  701 PN00013 
21 702 LG00102 
21 703 Inactivation of NOS by 2-ethylaminoguanidine 
21  704   
21 705 Second order rate constant k2 
21 706 6.70E-05 
21 707 M-1s-1 
21 708 
Wolff DJ, Gauld DS, Neulander MJ, Southan G. (1997) Inactivation of nitric oxide 
synthase by substituted aminoguanidines and aminoisothioureas. J Pharmacol Exp 
Ther; 283(1): 265-73 
… … … 
510  701 PN00132 
510 702 PN00054 
510 703 The inhibition of mini-collagenase by TIMP-1 
… … … 
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Table 4.4. Data structure of molecule table MOL_TYPE 
 
ID Concept Data Type Size (bytes) Occurrence in an entry 
711 Molecule ID Text 10 Once 
712 Name Text 20 Once 
713 Synonym Text 200 Null, once or more 
714 Type Text 20 Once 
715 CAS RN Text 100 Once or more (ligand) 
716 Formula Text 50 Once (ligand) 
717 Classification Text 100 Optional 
718 SWISS_PROT AC Text 100 Once or more (protein) 
719 Function Text 200 Once (protein) 
720 Tissue Distribution Text 100 Optional 
721 3D Structure Infomation (PDB) 
Text 100 Optional 
722 Nucleic Acid Information (NDB) 
Text 20 Optional 
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Table 4.5. Examples data of table MOL_DATA 
 
AC TYPE VALUE 
… … … 
32 711 PN00007 
… … … 
255  711 PN00013 
255 712 Nitric oxide synthase isoforms 
225 713 NOS 
255 714 Protein 
255 715  
255 716  
255 717  
255 718   
255 719 
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation 
through a cgmp-mediated signal transduction pathway. No mediates vascular endothelial 
growth factor (vegf)-induced angiogenesis in coronary vessels and promotes blood clot. 
… … … 
470  711 LG00007 
470 712 Oxygen 
470 713 
CCRIS 1228| EINECS 231-956-9| HSDB 5054| Hyperoxia| LOX| Liquid oxygen| 
Oxigeno [Spanish]| Oxygen| Oxygen molecule| Oxygen, liquified| Oxygen-16| Oxygene 
|Pure oxygen 







KDBI has a web interface at http://xin.cz3.nus.edu.sg/group/kdbi/kdbi.asp, which is 
shown in Figure 4.1. The kinetic data for a binding event is searchable by several methods. 
One method is via the name of participating molecules (protein, nucleic acid, small 
peptide, ligand or ion). An entry can also be searched through a SWISS_PROT AC 
number for a protein or the CAS number for a small molecule ligand. Moreover, keyword-
based text search is also supported. To facilitate convenient access to relevant data, a 
partial list of proteins is provided. Searches involving combination of these methods or 
selection fields are also supported.  
 
The search is case insensitive and wild cards are supported. In a query, a user can specify 
full name or any part of the name in a text field. Wild character of '*' and '?' is allowed in 
text field. Here, '?' represents any one character and '*' represents a string of characters of 
any length. For example, input of 'reductase' in the molecule field finds entries containing 
'reductase' in their name, such as NADPH-adrenoferredoxin reductase, NADH-CoQ 
recuctase, cytochrome P450 reductase, 5-alpha reductase, thiol-disulfide oxidoreductase, 
etc. On the other hand, input of NAD% reductase finds all the reductase start their names 
with 'NAD'. In this case, '*' represents ' PH-Adrenoferredoxin' and 'H-CoQ' respectively. 
 
The result of a search is illustrated in Figure 4.2, in which all events that satisfy the search 
criteria are listed. This list includes the name of the participating molecules as well as the 
description of the corresponding event. The related kinetic data can be obtained by 
clicking the “Kinetic data” button of a selected event.  The page of kinetic data, as shown 
in Figure 4.3, provides detailed description about the reaction equation (while available), 
CHAPTER 4 109
the kinetic data given in the literature, and the source of the literature. Further information 
about the participating molecules can be obtained by clicking the name of the respective 
molecules. As shown in Figure 4.4, the corresponding molecular information page 
provides the name, synonym, SWISS_PROT access number for a protein or CAS number 
for a small molecule ligand, classification and formula for a small molecule ligand (while 
available), and the function, tissue distribution and cross-link to SWISS_PROT database 
[Bairoch, 2000] for a protein. Moreover, hyperlinks are provided to facilitate access to the 
relevant reference in Medline and available 3D structural entries in PDB [Berman et al., 
2000]. For a nucleic acid, hyperlink to its available 3D structural entries in NDB is also 
provided [Berman et al., 1992]. 
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4.1.3 Statistics and analysis of KDBI 
 
KDBI currently contains 8273 entries of biomolecular binding or reaction events. There 
are a total of 1380 proteins, 143 nucleic acids, and 1395 small molecules (ligands and ions) 
included in the database. The distribution of the molecules is shown in Figure 4.5. The 
majority of the interactions kinetically studied by researchers are ligand-protein, protein-
protein, and protein-nucleic acids interactions, which represent 45.7%, 25.4%, and 15.3% 
of all the bio-molecular interaction entries, respectively (Table 4.6). It is noted that this 
statistics on the bio-molecular interactions is based on the incomplete collection of 
published kinetic information from year 2002 to year 1990. Work is still underway to 
collect kinetic data published in earlier years or in other resources. This is expected to 
significantly increase the number of entries of the database in the near future. This 
distribution of bio-molecular interactions containing kinetic information may be changed 
after new data are added. The kinetic information provided in KDBI is diverse, and 
includes the rate constants such as association rate constant, dissociation rate constant and 
order rate constants and different equilibrium constants. The types of kinetic constants 
collected by KDBI are list in Table 4.7. Studying the entries in detail, several facts are 
found: 1. Different kinetic analysis methods on the same interaction (same in both 
molecules and bio-event) may lead to the different kinetic value. However, the difference 
is normally not significant. 2. For the same interaction measured by same method, the 
value of same kinetic items may be significantly different due to different experimental 
condition. Thus, a complete entry should include both the method and condition as well as 
the kinetic value. 
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Figure 4.5. The distribution of molecules in KDBI database 
 




















Ligand - Ligand 195 2.4 78
Ligand - Nucleic Acids 115 1.3 52
Ligand - Protein 3783 45.7 1697
Protein - Protein 2105 25.4 927
Protein - Nucleic Acid 1263 15.3 720
Nucleic Acids - Nucleic Acids 434 5.2 326
Cell – Others 73 0.9 41
Ion – Others 187 2.3 108




Table 4.7. The types of kinetic constants information provided by KDBI 
 
Rate constant Equilibrium constant 
Association rate constant (kass) Association constant (Kass) 
Dissociation rate constant (kdiss) Dissociation constant (Kdiss) 
Order rate constant (k1, k-1, k2…) Affinity constant (Ka) 
Cytalytic rate constant (kcat) Inhibition constant (Ki) 
Inhibitary rate constant (ki) Michael constant (Km) 
On rate constant (kon) Order constant (K1, K-1, K2…) 
Off rate constant (koff) 
Channel open rate constant (ko) 
Channel close rate constant (kc) 
Forward rate constant (kf) 
Backward rate constant (kb) 
Observed rate constant (kobs) 
Apparent rate constant (kapp) 
Peudo-order rate constant (kp) 
Exchange rate constant (ke) 





4.2 Knowledge Discovery for KDBI: Construction of Protein-
Protein Interaction Network 
4.2.1 The need of the construction of protein-protein interaction 
network 
 
It is estimated, from the study of human genome, that there are about 100,000 or more 
proteins in a human body. A portion of them has been well studied for their structures and 
functions by experiment. The functions of some of the proteins are probed by means of 
sequence analysis including sequence homology and share a motif with proteins of known 
function. In many instances, a protein carries out its function by interaction with other 
molecules and these interactions are essential in a broad spectrum of biological processes 
including regulation of metabolic pathways, immunologic recognition, DNA replication, 
progression through the cell cycle, and protein synthesis [Alberts et al., 1989]. The 
construction of the protein-protein interaction network is thus a useful approach to 
facilitate the understanding of the mechanisms of various biological processes. There are 
several protein-protein interaction databases available on-line. The Biomolecular 
Interaction Network Database (BIND) [Bader et al., 2003] archives biomolecular 
interaction, complex and pathway information. It provides for the storage of interactions 
or complexes involving all kinds of biomolecules (protein, DNA, RNA, and small 
molecules) down to the atomic level and provides a home for annotated research findings 
and externally published scientific data. The information of protein complex derives from 
mass spectrometry based proteomics as well as from high-throughput Genetic interactions. 
The Database of Interacting Proteins (DIP) documents experimentally determined protein-
protein interactions, which is useful for understanding protein function and protein-protein 
relationships, studying the properties of networks of interacting proteins, benchmarking 
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predictions of protein-protein interactions, and studying the evolution of protein-protein 
interactions. The BindingDB [Chen et al., 2001] is a public web-accessible database of 
measured binding affinities for biomolecules, genetically or chemically modified 
biomolecules, and synthetic compounds. In addition to these databases focused on protein-
protein interaction, there are some pathway databases available on-line, which represent 
the biological processes or protein interactions as block diagrams. These databases include 
the metabolic pathway databases KEGG [Kanehisa et al., 2002], the Signaling PAthway 
Database (SPAD) [http://www.grt.kyushu-u.ac.jp/spad/], the Biochemical Pathways of 
ExPASy [http://www.expasy.org/cgi-bin/search-biochem-index]. These databases are 
useful tools for facilitating the understanding of the protein functions and biological 
processes. Some pathway databases also provide the quantitative information such as the 
Database of Quantitative Cellular Signaling, which includes reaction schemes, 
concentrations, rate constants, as well as annotations on the pathway models 
[Sivakumaran, 2003]. Such databases provide further insights into cellular functions and 
processes; however, the kinetic studies are limited to the known pathways. Since 
quantitative understanding of biological processes should explicitly specify the kinetics of 
all chemical reaction steps in a pathway, it is very meaningful to construct a protein-
protein interaction network with kinetic information. Here, in this work, such protein-
protein interaction network is constructed for the kinetic study and visualization of 
protein-protein interaction. As shown in the Table 4.6, the number of protein-protein 
interaction entries accounts of about 25% of the total number of entries in our Kinetic 
Data of Biomolecular Interaction (KDBI) database. As these entries provide kinetic data 
of protein-protein interactions, such a network is particularly useful for quantitative as 
well as qualitative study of biological pathways. 
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4.2.2 Procedure of protein-protein interaction network construction 
 
The basic idea to construct the protein-protein interaction network is to connect a number 
of single “nodes” to form the network. Each “node” in the protein-protein interaction 
network is actually a unique protein molecule. The definition of unique protein in network 
construction is based on following rules: (1) proteins having same genetic identity such as 
name, function and sequence, but coming from different species are considered as one 
same protein, although these proteins give different kinetic values when they bind to the 
same molecule. (2) Wide-type protein and its mutants can be treated as one molecule, 
although they normally show different binding abilities binding to same molecule. For 
example, alcohol dehydrogenases from Homo sapiens and from rats will be served as 
same “node” in the network; wild type alcohol dehydrogenases and their mutants are also 
considered as same “node”. A PERL program is written to re-identify the proteins in 
KDBI. At the same time, a protein-protein interaction table is generated automatically by 
the program to store the network information. An example of the table is shown in Table 
4.8. Each record of this table consists of two parts of information: the left side of symbol 
“<-->” is the unique protein ID of the “starting node”, while the right side part is the ID 
list of the proteins which interact with this specific protein, so-called the “ending nodes”. 
It is noted that each protein on the right side of entries also acts as a “starting node” of 
another entry in the table. By linking the “starting node” to each protein of the “ending 
nodes”, each entry of the interaction Table 4.8 forms a small protein-protein interaction 
“tree”. Following the same method, a number of such small interaction “trees” are thus 
generated. Binding these small “tree” together through the common “nodes”, the protein-
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protein interaction network is constructed. Due to long and unformatted protein names, the 
network is constructed using unique molecule IDs instead of molecule names for better 
layout. However, to illustrate the relationship between the proteins, the mapping of 
molecule IDs to corresponding proteins is also listed following the protein network. The 
kinetic information of protein-protein interaction can be acquired by clicking the 
connecting lines between two proteins, which will pass the respective proteins as 
keywords to the KDBI search engine. 
 
4.2.3 Result and analysis of the protein-protein interaction network 
construction 
 
An example result of the network is shown at the Figure 4.6. The protein interaction 
network is shown at different levels. For example, the molecule, Leukocyte elastase 
PN00440 (start node, and level 1 of network), interacts with 5 molecules PN00439, 
PN00462, PN0463, PN00498 and PN00714 (level 2). And further, PN00463 interacts with 
11 proteins: PN00115, PN00123, PN00128, PN00169, PN00225, PN00296, PN00465, 
PN00468, PN00480, PN00523, and PN00530 (level 3); Molecule PN00128 (Neutrophil 
elastase) further interacts with molecule PN00498 (level 2 or level 4); Molecule PN00480 
further interacts with molecules PN00714 (level 2 or level 4) and PN00296 (level 4). For 
the 5 molecules at level 2 of network, three of them PN00463, PN00498 and PN00714 
continue the network to level 3, the other two molecules terminate the interaction due to 
the limitation of the data. It is noted that there exist a loop interaction among molecules 
Leukocyte elastase (PN00440), Alpha-1-antitrypsin F (PN00463), Neutrophil elastase 
(PN00128) and Alpha-1-antitrypsin M (PN00498). Another loop is among proteins Alpha-
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1-antitrypsin F (PN00463), Miniplasmin (PN00480) and Plasmin (PN00296). The loop 
interactions in the network are often related to non-leaner bio-events, which play 
important role in the study of protein profiling and regulation. The construction of the 
protein-protein interaction network is still preliminary. With more data available in KDBI, 
along with the improvement of visualization application in this project, the network will 
become more complete and user-friendly. It is expected combining with the existing 
metabolic pathway or regulatory pathway maps and that protein-protein interaction 
network may fill up the imaginary connection in the pathway maps, as well, the pathway 
maps will endow the interaction network with a broad view of biological processes. 
 
Other than the protein-protein interaction network, protein-ligand interaction network 
based on KDBI is also a promising application for drug discovery. By studying the affinity 
of single protein-mulitple ligands interactions, one can develop a view of what ligands 
may interact with a protein. Such structure and activity relationship (SAR) study is 
recognized as a feasible approach for drug discovery. On the other hand, by studying the 
single ligand-multiple proteins interactions, one could explore the possibility of ligands as 
drug candidates: Does a ligand bind to expected therapeutic targets? Can it be transported 
to the therapeutic site by ADME associated proteins? Will it lead to serious side effects by 
interaction with targets?  
 
Another potential application of KDBI is the mathematical simulation of biological 
pathways. The availability of kinetic information enables the mathematical modeling of 
bio-molecular interactions. The modeling is done to further improve the understanding of 
cellular processes or biological pathways and identify potential therapeutic applications. 
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Similar achievement have been published [Grossniklaus et al., 1996; Fussenegger et al., 




Table 4.8. The protein-protein relationship 
 























PN00468-->Porcine pancreatic elastase 
PN00480-->Miniplasmin 





CHAPTER 5 CONCLUSION 
 
 
5.1 Integration Of Subject-Specialized Databases for 
Comprehensive Information 
 
In the early days, when biological databases were first opened for public access, the 
general opinion was doubtful and hesitant. Now, it has become a routine step for the 
researchers to make use of the biological databases to answer the questions before the 
expensive experiments are carried out. The biological databases ranges from the large-
scale primary archiving projects such as GenBank and SWISS_PROT, to the individual 
and subject-specialized databases such as our DART and KDBI.  Database systems today 
are facing the task of organizing the ever-increasing amount and complexity of biological 
data in the demand of different user communities. 
 
The general databases are normally large in size and contain raw data of sequence, 
structure, or literature. It is thought that they are databases rather than knowledge bases, 
which describe miscellaneous objects according to the database schema, but no 
representation of general concepts and their relationship [Hafner et al., 1996]. As a result, 
further efforts are required to interpret the raw data so that they can be practically 
understood and used by communities having different interests. To meet the need of 
different communities, the subjected-specialized databases are constructed. Compared to 
the general databases, they are normally compact in size and focused on providing 
information about certain biological fields. The subject-specialized databases collect the 
subject related information from different data source on purpose. For example, the drug 
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adverse reaction target database (DART) only collects the information concerning the 
drug adverse effects and organizes them in context; such information can be found in 
different general sources that are isolated.  
 
Users may be discouraged when they attempt to further explore some interested concepts 
in subject-specialized databases. A solution is to build the cross-links to other general or 
subjected-specialized databases containing concepts of interests. The process is called 
integration of databases. The integration of databases enables the subject-specialized 
databases to be compact, however, it provides more comprehensive information. For 
example, KDBI database cross-links to the general protein database SWISS_PROT for the 
additional protein properties such as sequence similarity; it also cross-links to the PDB for 
protein 3D structure information. The integration is achieved by sending keywords to the 
search engines or retrieval systems of respective databases. This level of integration is 
indirect and sometimes contains multiple intermediated steps. There is another level of 
data integration, which is direct and compact. The integration involves different local 
databases, which share groups of information. Normally, the integration process is taking 
place during the initial construction of databases. At that stage, database developers 
should determine which information components may be linked to other databases, and 
how table(s) storing common information components be shared in different databases. 
Any update of these common table(s) will affect all the connected databases so that it 
saves the workload for the overlap information. For example, as shown in Figure 5.1, 
several subject-specialized databases such as DART, KDBI, Therapeutic Target Database 
(TTD) [Chen et al., 2002], and ADME associated protein database (ADME-AP) [Sun et 
al., 2002] can share the same ligand information table since they require similar 
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information of ligands. And information of protein properties is collected from different 
source, but deposit in one table, which is also shared by different databases.  
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5.2 Proposal of a New CADD Approach: Drug Target Databases 
Aiding Drug Discovery 
 
Protein targets play a crucial role in the disease etiology studies, pharmacokinetics studies 
or toxicity studies. Identification of these target proteins may help to enhance the efficacy 
of drugs and reduce the side effects. At least, three kinds of target proteins are important 
in drug discovery: therapeutic targets, ADME (absorption, distribution, metabolism, and 
excretion) associated proteins, and adverse drug reaction (ADR)/toxicity targets. In this 
work, the adverse drug reaction target database (DART) is created to help in the 
identification of potential toxicity targets and hence filter out the serious toxicity inducing 
drug candidates. The other two target databases therapeutic target databases TTD [Chen et 
al., 2002] and ADME-associated protein databases ADME-AP [Sun et al., 2003] were 
also previously developed by our research group.  
 
These three target databases participate the computer-aided drug design at different stages. 
As shown in Figure 5.2, TTD help the selection of therapeutic targets during the disease 
etiology study and it is also involved in the efficacy study. The compounds in the pools 
are filtered by binding studies on the therapeutic targets. ADME-AP database will further 
help to remove those candidates with delivery or metabolism problems. Following 
efficacy, selectivity and bioactivity studies, the potential drugs candidates will be passed 
to toxicity study, which is supported by the DART databases. These databases can be 
combined with computer-aided molecular modeling software such as the docking program 
INVODOCK to facilitate drug discovery virtually. An example is the drug safety 
evaluation study described in Chapter 3, where combinational applications of 
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INVODOCK and DART database successfully predicted adverse effects induced by 
investigational drugs. Similar application can also be used to predict the efficacy, 
bioactivity, and pharmacokinetic characteristics of potential drugs by including inclusion 
of specific databases such as TTD, ADME-AP and KDBI. In conclusion, databases 
supported CADD system may be a good method to facilitate drug discovery. However, it 
is also noted that the robustness of this system greatly depends on the completion of 
databases. As the result, continuous update of these databases may be the key factor for 
practical application of this computer-aided drug design system.  
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5.3 Proper Prediction of ADR Targets by SVMs 
 
Based on algorithm of Support Vector Machines (SVMs) and its applications in the 
proteomics and genomics studies, it appears that SVMs can be very useful in mining 
unknown patterns or features based on the primary sequence of proteins or nucleic acids. 
This view is further supported by our study on the prediction of ADR target proteins using 
SVMPROT. The overall accuracy of about 90% in the ADRs proteins prediction may 
prompt the identification of ADR targets. However, it is also noted that the accuracies for 
the prediction of positive samples and negative samples are different, 96.8% and 87.4% 
for positive and negative prediction, respectively. 
 
The different performance of SVM on prediction and exact classification of positive and 
negative data is essentially due to the definition of positive and negative data for the 
learning model building. SVM learns to be optimal hyperplane classifier and able to 
separate the positives and negatives based on the computation of certain vectors 
(descriptors). If all the features describing the positive/negative data were selected to 
construct the hyperplane, the prediction accuracy of positives/negatives should reach close 
to 100% after optimization. However in practical, this may be difficult. One reason is the 
inability to determine all the essential descriptors for the proteins. An alternative solution 
is to include all possible descriptors for these proteins. The advantage is avoiding 
information loss; on the other hand, it also increases noise-to-signal ratios and the 
computational time. SVM optimization procedure and feature vector selection algorithm 
may also be improved by adding additional constraints and by incorporating independent 
component analysis and kernal functions such as PCA in the preprocessing steps.  
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Compared to the shortcoming of SVMs, the definition of data is also critical for the 
accuracy of classification. The definition of data is the problem of how to prepare the 
positive and negative datasets, especially for training and testing. Well-prepared 
positive/negative data will significantly increase the accuracy of SVM predictions and 
compensable for inadequate protein descriptors. A meaningful preparation should consist 
of two elements: firstly, all features for the separation of positives/negatives should be 
presented; and secondly, the pre-definition of positives/negatives should be correct and 
unambiguous. The first element covers the incomplete collection of the protein types. If 
one protein type with distinct features is not used for the model construction (here, the 
construction of hyperplane in SVM learning process), it will be very likely that all proteins 
of this type cannot be properly classified. This problem may be largely responsible that for 
the low accuracy of positives in our ADRs target proteins prediction. The incomplete 
collection of ADR target proteins significantly affects the performance of SVMs. 
However, it is believed that with more ADRs protein types found, the accuracy will 
increase. The second element is also important since incorrect assignment of positives and 
negatives may lead to incorrect hyperplanes for separation of input data. This will affect 
the accuracy of predicting both positives and negatives. A possible solution is to remove 
ambiguous data from the positive/negative datasets or reassign. A repetitive training 
process has positive effect on the accuracy of classification. 
 
Other than the problems of descriptors and definition of the data, there are some more 
factors also affecting the performance of SVMs such as the size of data for training, the 
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protein sequence complement. Nevertheless, SVMs is a promising and plausible new 
approach for protein classification.   
 
5.4 Information Extraction from Biomedical Literature Using 
Text Mining 
 
Biomedical literature plays an important role in integrating, annotating and 
communicating experimental results and their implications. The information encapsulated 
in the literature is high and diverse, however, the distribution of the information is often 
diffuse and unrecognizable. In recent years, text mining technologies have been 
introduced into the life science to identify patterns of information and rules of information 
retrieval. In this work, two databases, DART and KDBI, are constructed by extracting the 
useful information from the public literature sources, and the text mining technology is 
also studied to help with information collection. 
 
The semantic approach is common method in text mining, which can be realized at three 
levels: words, keywords and concepts. In this work, two lists of keywords are manually 
assigned for the feature selection: one is the keyword list of adverse effects and the other 
one is the distinct protein list. The ADR keywords are manually collected from the clinical 
reports. The list of protein keywords is generated by removing the redundant entries from 
SWISS_PROT protein list. Compared to the automatical identification of keywords, the 
manually assigned keywords are more accurate and practical. Therefore, the list of adverse 
reaction keywords is collected manually. Two rules are applied to constrain the abstracts: 
the abstract should include both the ADR keywords and protein, and the keywords should 
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be closely related. In this study, the relationship of the keywords was simply identified by 
the distance between the keywords. It is assumed that two keywords are related if they 
appear in the same sentence or an adjacent sentence. Thus a maximum distance is used to 
check the relationship between two keywords. This maximum distance is an empirical 
value obtained by many times of text mining. Unfortunately, keywords close in distance 
doesn’t always mean the direct relationship between them. More restricted conditions may 
be helpful to filter out the unrelated abstracts containing both ADR and protein keywords. 
A better solution is to use concept representation instead of keyword representation to 
extract information. It is reasonable to believe that the evolution of text mining from 
words and keywords to concepts will greatly improve the extraction of truly useful 
information from literatures. However, further improvement of text mining algorithm is 
not carried out in this study due to consideration of research cost. The identification of the 
ADR target related information is difficult; therefore, any useful information-containing 
abstract is critical for the completeness of database. To protect from loss of useful 
information and provide correct data, manual editing of selected abstracts after simple 
keyword text mining is carried out.   
 
The kinetic information of KDBI is collected completely manually. The reason for manual 
collection of information, instead of automatically mining by robot, is because of the 
insufficient electronic papers containing kinetic information. Unlike the information 
concerning adverse drug reactions, where the clues (keywords) and even the information 
itself often appear in the abstracts, generally, the majority of kinetic values are available 
only in the full papers in the forms of tables or lists. Without processing the full papers, 
much useful kinetic information will be missing, thus a nearly complete collection of 
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kinetic values becomes impossible. Unfortunately, the full papers in many journals are 
only available for a fee; moreover, the papers in electronic version feasible for text mining 
are limited in volume (normally, the volumes after year 1990s). Given that many kinetic 
values are listed in tables, reaction equations or figures, it would be harmful if the robots 
cannot properly determine which table contains kinetic information and what the useful 
kinetic information in the table is. Especially for those kinetic values appearing in the 
reaction equations, the robot extraction of information is almost impossible. The 
difficulties in obtaining the electronic version of full papers and efficiently extracting 
useful information from papers lead to impossible of using robots to gather kinetic 
information. The decision is also supported by the difficulty of verification of kinetic data 
generated by text mining. The verification of data is critical for a good publicly accessible 
database. The one-by-one checking process is always as time-consuming as manual 
information collection. Considering all conditions of information collection, manual 
collection is adopted finally. 
    
In conclusion, text mining is promising in information extraction from the flood of 
documents. However, an absolutely depend on text mining to collect information from 
biological documents is impractical, especially in the development of public databases. 
The difficulties come both from the limitation of natural language recognition and the 
characteristics of biological fields, e.g., the very unstructured nature of biomedical 
documents, the confusion of biological nomenclature, and the diversity of biological 
information. The shortcomings of biomedical information sources are a historical 
problems, and little work can be done to change the situation. It is expected that some 
control measures in biological/medical fields such as the standardization of the protein 
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nomenclature can be accepted by all researchers in the future. Then information will be 
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ALGORITHM OF SUPPORT VECTOR MACHINES 
 
 
Support Vector Machine (SVM) is a learning technology introduced in 1979 [Vapnik et 
al., 1979]. However, it receives increasing attention since it has been re-introduced by Dr. 
Burges [Burges et al., 1998]. The principle of the SVM method is to learn from the related 
examples as a basis for predictions. In other words, SV algorithm is the connection 
between learning theory and practical applications. Generally, the algorithm of Support 
Vector Machines is composed of four stages: learning pattern recognition, hyperplane 
classification, kernel functions for feature spaces, and SV function estimation.  
 
Learning Pattern Recognition 
The start of support vector learning process is the problem of learning how to recognize 
patterns. A function f: RN → {±1} is estimated using training data set (xi, yi) for pattern 
recognition. xi are the N-dimensional patterns and yi are the class labels, which are under 
the same probability distribution P(x, y),  
}1{),),...(,(),,( 2221 ±∈ XRyxyxyx Nll       (1) 
The function f is well generalized so that the training dataset (xi, yi), i = 1, 2, …, l, satisfy f 
(xi) = yi. Through the learning, the function f should be able to correctly classify new 
examples (xj, yj), satisfying f (xj) = yj. However, the fact is the well generalized function f 
from the training dataset doesn’t have to be well generalized for the unseen new data. That 
is, for any test dataset (xj, yj) ∈ RN X {±1} and {x1, x2, …, xj} ∩ {x1, x2, …, xi} = { }, 
there exists another function f* such that f* (xi) = f (xi) for all i = 1, 2, …, l, yet f* (xj) ≠ f 
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(xj) for all j = 1, 2, …, l. Hence, there is no means to decide that which of these two 
functions is preferable, and only minimizing the training error thus does not imply a small 
test error. To minimizing the test error, it is good to restrict the class of functions that the 
machine learning can implement to one with a capacity that is suitable for the amount of 
available training data. The capacity is the ability of the SV machine to learn any training 
set without error. The statistical learning theory [Vapnik et al., 1974; Vapnik et al., 1979] 
or the VC (Vapnik-Chervonenkis) theory is thus introduced to add the bounds on the test 
error. The minimization of these bounds, which depend on both the empirical risk 
(training error) and the capacity of the function class, leads to the principle of structural 
risk minimization [Vapnik et al., 1979]. The best-known capacity concept of VC theory is 
the VC dimension, defined as the largest number h of points that can be separated in all 
possible ways using functions of given class. If the h < l is the VC dimension of the class 
of functions that the machine learning can implement, then for all functions of that class, 




ηφαα +≤       (2) 











= .     (3) 
By the bound, for a finite amount of training dataset satisfying the distribution 
)()(),( yPxPyxP ⋅= ,        (4) 
which means the pattern x contains no information about the label y, zero training error is 
possible. In order to reproduce the random labelings (increasing the capacity), a large VC 
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dimension h is required; the increase of h is accompanied by the increase of the confident 
term φ (4), thus the small test error will not be supported by the bound (3) and the 
accuracy is lowered. However, too little capacity will make the learning meaningless. 
Therefore, in order to get nontrivial predictions from (3), the function space must be 
restricted such that the capacity is small enough. For the given finite amount of training 
data set, there should exist a function having a balance between the classification accuracy 
and the capacity. 
 
Hyperplane Classifiers 
To design learning algorithms as well as finding the balance for machine learning between 
accuracy and the capacity, the capacity for a class of functions should be computed. 
Vapnik and Lerner [Vapnik et al., 1963], and Vapnik and Chervonenkis [Vapnik et al., 
1964] proposed a learning algorithm for constructing the decision function f from 
empirical data for separating the class of hyperplanes. The class of hyperplanes is the base 
of SV classifier,  
0)( =+⋅ bxw   w ∈ RN, b ∈ R,      (5) 
where w is the weight vector and the corresponding decision functions 
))(()( bxwsignxf +⋅=        (6) 
Among all hyperplanes separating the data, there exists a unique one, optimal hyperplane, 
yielding the maximum margin of separation between the classes, 
bw,
max },...,2,1,0)(,R||:min{|| N libxwxxx i ==+⋅∈− ,   (7) 
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and the capacity of the learning algorithm decreases while the margin increases (Figure 1) 
[Hearst et al., 1998]. The construction of the Optimal Hyperplane is by solving the 
following optimization problem: 
minimize 2||||
2
1)( ww =τ       (8) 
subject to , i = 1, 2, …, l.     (9) 1))(( ≥+⋅⋅ bxwy ii
To solve the constrained optimization problem, the Lagrangian and the Lagrange 










1),,( αα     (10) 
where 0≥iα . The Lagrangian L has to be minimized with respect to the primal variables 
w and b and maximized with respect to the dual variables αi. w here has an expansion 
in terms of a subset of the training patters, called Support Vector while α∑= i iii xyw α i is 







0α 0≥iα , the hyperplane 








))(()( α       (11) 
where b is calculated by 
0]1))(([ =−+⋅⋅ bwxy iiiα , i = 1, 2, …, l.     (12)
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Figure 1. The binary classification and the hyperplane. 
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Feature Spaces and Kernels 
 
To construct SV machines, the optimal hyperplane algorithm should allow a method for 
computing dot products in feature spaces nonlinearly related to input space. The basic idea 
is to map the data into some other dot product space, so-called the feature space, F via a 
nonlinear map,  
FRN →:φ          (12) 
and perform the above linear algorithm in F. This requires the evaluation of dot products 
by a simple kernel function,  
))()((:),( yxyxk φφ ⋅= .       (13) 
If F is high-dimensional, then kernel function, polynomial kernel,  
dyxyxk )(),( ⋅= .        (14) 
can be shown to correspond to a map φ into the space spanned by all products of exactly d 

















⎛=⋅ ,      (15) 
defining ),2,()( 2221
2
1 xxxxx =φ . For every kernel that gives rise to a positive matrix 
, a map φ can be constructed.  ijji xxk )),((
 
SV function estimation 
 
To construct SV machines, one computes an optimal hyperplane in feature space. In 
practice, such a separating hyperplane may not exist due to high noise level of data. Thus 
the slack variables ξ are introduced. The modified classifier will generalized well by 











1),( ξξτ        (16) 
 with the relaxed constraints, 
iii bxwy ξ−≥+⋅⋅ 1))(( , i = 1, 2, …, l.     (17) 
and 
0≥iξ ,  i = 1, 2, …, l.       (18) 
C is the upper bound on the Lagrange multipliers αi, 








The concept of the margin is specific to pattern recognition. To generalize the SV 
algorithm to regression estimation [Vapnik et al., 1995], an analogue of the margin is 
constructed in the space of the target values y by using Vapnik’s ε-insensitive loss 
function, 
}|)(|,0max{:|)(| εε −−=− xfyxfy .     (20) 
In input space, the hyperplane corresponds to a nonlinear decision function, which is 
determined by the kernel (Figure 2) [Cortes et al., 1995; Vapnik et al., 1995]. By the 
choice of different kernel functions, different architectures can be achieved. Surprisingly, 
the different kernel functions lead to very similar classification accuracies and SV sets 
[Schölkopf et al., 1995]. In this case, the learning algorithm tries to construct a linear 
function in the feature space such that the training points lie within a distance ε > 0. The 
algorithm can be modified such that ε need not be specified a priori. Instead, and an upper 
bound is specified on the fraction of points and the corresponding ε can be 10 ≤≤ v
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ii xfyvlCw       (21) 




R the set of reals 
N dimensionality of input space 
F feature space 
xi input patterns 
yi target values (class) 
l number of training examples 
w weight vector 
b constant offset (threshold) 
h VC dimension 
ε parameter of the ε-insensitive loss function 
αi Lagrange multiplier 
α vector of all Lagrange multipliers 
ξi slack variables 
||.|| 2-norm (Euclidean distance), )(||:|| xxx ⋅=  
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Linear separation of input points (a) does not work well: a reasonably sized margin 
requires misclassifying one point. A better separation is permitted by nonlinear functions 
in input space (b), which corresponds to a linear function in a feature space (c). Input 
space and feature space are related by the kernel function. 
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